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CHAPTER 1. GENERAL INTRODUCTION 
 
1. Introduction 
 
Since the 1970s, Campylobacter, a Gram-negative microaerobic bacterium, has 
emerged as a major foodborne pathogen and a common causative agent of human 
enterocolitis. Campylobacter jejuni is responsible for approximately 90% cases of human 
campylobacteriosis, followed by Campylobacter coli, which accounts for approximately 10% 
cases of human campylobacteriosis. Signs and symptoms of campylobacterosis often start as 
a cramping pain in the abdomen, followed by watery or inflammatory diarrhea. Some 
individuals may develop fever, headache, dizziness and myalgia. Campylobacter infection 
causes more than 2 million cases of diarrhea each year in the U.S. alone. C. jejuni infections 
in humans may also trigger a degenerative neurological disorder called Guillain-Barré 
syndrome.  
 
Majority of Campylobacter infections are mild, self-limiting and usually resolve 
within a few days, no specific treatment is required for most patients with Campylobacter 
enteritis. However, in specific clinical circumstances such as in severe infections, prolonged 
illness or where the patient is pregnant, young, elderly, or has compromised immunity, 
antimicrobial treatment is usually warranted. Fluoroquinolone (FQ) antimicrobials are one of 
the antibiotics that are often prescribed for clinical treatment of diarrhea caused by enteric 
bacterial pathogens including Campylobacter. However, Campylobacter is increasingly 
resistant to FQ antimicrobials and FQ-resistant (FQR) Campylobacter, developed in food-
producing animals, can be transmitted to humans via the food chain, which has become a 
major concern for public health. In Campylobacter, the main targets of FQs are DNA gyrases, 
and resistance to FQ antimicrobials is mediated by point mutations in the quinolone 
resistance-determining region (QRDR) of gyrA in conjunction with the function of the 
multidrug efflux pump CmeABC. Acquisition of high-level FQ resistance in Campylobacter 
does not require stepwise accumulation of point mutations in gyrA. Instead, a single point 
mutation in gyrA can lead to clinically relevant levels of resistance to FQ antimicrobials. 
Specific mutations at positions Thr-86, Asp-90 and Ala-70 in GyrA have been linked to FQ 
 
 
 
2 
resistance in C. jejuni. The Thr-86-Ile mutation in GyrA confers a high-level resistance to 
fluoroquinolone. One unique feature of FQ resistance development in Campylobacter is the 
rapid emergence of FQR mutants from a FQ-susceptible (FQS) population when treated with 
FQ antimicrobials and C. jejuni possesses a high mutation rate to FQ resistance. The 
rapidness and magnitude of FQ resistance development in Campylobacter in response to FQ 
treatment suggest that both selective enrichment of pre-existing spontaneous mutants and 
adaptive gene expression may contribute to the emergence of FQR Campylobacter, but how 
Campylobacter responds to FQ treatment is unknown. Once developed, FQR Campylobacter 
carrying the Thr-86-Ile change in the GyrA subunit of DNA gyrase can persist in the absence 
of antibiotic selection pressure. Notably, FQR Campylobacter carrying the Thr-86-Ile 
substitution in the GyrA subunit of DNA gyrase outcompeted the FQS strains in chickens, 
suggesting that acquisition of FQ resistance enhances the in vivo fitness of FQR 
Campylobacter. How the resistance-conferring mutation affects Campylobacter fitness 
remains to be determined. 
 
To close these important gaps in our understanding of the mechanisms underlying the 
rapid emergence of FQR mutants and fitness of the FQR mutants, we conducted a series of in 
vitro and in vivo studies to determine how Campylobacter responds to FQ treatment, what 
facilitates the emergence of FQR mutants in Campylobacter, and what are the molecular 
mechanisms contributing to the enhanced fitness in FQR Campylobacter. The findings from 
this project will significantly improve our understanding of the molecular mechanisms 
underlying the development of FQR Campylobacter and the fitness of the FQR 
Campylobacter and will facilitate the design of strategies to reduce the emergence and spread 
of FQR Campylobacter. 
 
2. Dissertation Organization 
 
This dissertation is organized in the alternative format with five chapters. Chapter 1 
contains a general introduction. Chapter 2 contains a literature review. Chapter 3 through 5 
each contains a manuscript published or to be submitted to the ASM journals. Chapter 6 is 
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the general conclusion. At the end of each chapter are appended references cited followed by 
tables and figures.  
 
 
 
 
4 
CHAPTER 2. LITERATURE REVIEW 
 
1. Campylobacter: The Organism  
 
1.1 Taxonomy 
 
The pathogenic bacteria Campylobacter spp. were first observed and described as 
non-culturable spiral-shaped or Vibrio-like bacteria in 1886 by Theodor Escherich (130) and 
first isolated from an aborted bovine fetus in 1913 by McFadyean and Stockman (36). At that 
time, these bacteria were classified in the genus Vibrio. In 1963, based on their low G+C 
composition, their microaerophilic growth requirements, and their nonfermentative 
metabolism, Sebald and Veron transferred two of these Vibrio species, Vibrio fetus and 
Vibrio bubulus, into a new genus Campylobacter as Campylobacter fetus and Campylobacter 
bubulus, respectively. With the development of new isolation technique, additional 
Campylobacter-like organisms were isolated from a variety of human, animal, and 
environmental sources and some of those species were described and added to 
Campylobacter genus. In 1991, Vandamme and De ley accommodated the genera 
Campylobacter and Arcobacter into a new bacterial family, the Campylobacteraceae. 
Currently, the genus Campylobacter includes 18 species: C. jejuni, C. coli, C. concisus, C. 
curvus, C. fetus, C. gracilis, C. helveticus, C. hominis, C. hyointestinalis, C. insulaenigrae, C. 
lanienae, C. lari, C. mucosalis, C. rectus, C. showae, C. sputorum, C. upsaliensis and C. 
canadensis. Although most of the Campylobacter spp. have been associated with veterinary 
and human infections, C. jejuni and C. coli are the most important and major cause of food-
borne Campylobacter infection in humans. 
 
1.2 General characteristics of Campylobacter 
 
Campylobacter spp. are Gram-negative, nonspore-forming, S- or spiral-shaped rod 
bacteria that are approximately 0.2 to 0.8 µm wide and about 0.5 to 5 µm long (58). 
Although normally a curved-rod shape, other forms of Campylobacter such as spherical or 
coccoid occur in response to stress or deleterious conditions (47, 58). Most Campylobacter 
are motile with distinctive corkscrew-like darting motions, using a single polar, unsheathed 
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flagellum at one or both ends (58). Some Campylobacter species (C. gracilis) are nonmotile 
while some (C. showae) have multiple flagella (58).  
 
The members of Campylobacter spp. are slowly-growing, fastidious organisms and 
require a microaerophilic atmosphere for optimal growth (47, 201). Typical Campylobacter 
spp. requires an atmosphere containing approximately 3 to 15% O2 and 2 to 10% CO2 for 
optimal growth. Although most Campylobacter can grow at 37 °C, thermophilic 
Campylobacter spp. such as C. jejuni, C. coli, and C. lari show optimal growth at 42  °C on 
artificial media (47, 221). The ideal environment for recovery of Campylobacter is at 37 °C 
or 42 °C under the atmosphere containing approximately 5% O2, 10% CO2, and 85% N2. 
Campylobacter spp. are unable to utilize glucose and other hexoses as carbon sources. The 
main carbon and energy sources used by Campylobacter for growth are derived from the 
degradation of amino acid or tricarboxylic acid cycle intermediates (123, 124). Therefore, 
nutrient-rich media, such as Mueller-Hinton broth, are often used for culturing 
Campylobacter.  
 
Campylobacter spp. have a small genome of approximately 1.6-1.7 Mb with AT-rich 
DNA and low G+C content ranging from 29-34 mol% (183, 191). C. jejuni NCTC 11168 has 
1,643 open reading frames (ORFs) and it lacks plasmids (191). Other features found in the 
C..jejuni NTCT 11168 are the lack of insertional sequences or phage-associated sequences, 
and few repeat sequences (183). One of the most striking themes in the C. jejuni genome is 
the presence of hypervariable sequences encoding the biosynthesis or modification of surface 
structures such as flagellum, capsular polysaccharides, and lipooligosaccharides (LOS). 
 
2. Epidemiologic Aspects of Campylobacter Infection 
 
Campylobacter jejuni is one of the most prevalent bacterial foodborne pathogens in 
the United States and many other developed countries, causing more than 2 million cases of 
diarrhea each year in the U.S. alone (7, 75, 184, 214, 236). Person-to-person transmission of 
Campylobacter is rare, and the main source of human Campylobacter infection is via food, 
water, or milk contaminated by Campylobacter (11, 56, 75). In general, people can become 
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infected with Campylobacter spp. by four different ways: (i) by handling raw meats and meat 
products, (ii) by consumption of raw or undercooked meats, unpasteurized milk and dairy 
products, (iii) by consumption of foods that are usually eaten raw or without further cooking 
such as salads and breads, which may become cross contaminated with raw meats in the 
kitchen, or (iv) by direct contact with infected animals/pets (25, 224, 225). Domestic poultry 
are considered to be a major risk factor for human Campylobacter infection (7, 229). The 
correlation between the consumption of chicken meat and Campylobacter infection in 
humans has been demonstrated in several studies (74, 209, 226). C. jejuni is highly prevalent 
in the intestinal tract of market-age broiler chickens. Several survey studies revealed that at 
least 70% of retail chickens sold in the United States are contaminated with Campylobacter 
(270). The sources of C. jejuni infections in poultry have not yet been elucidated. Potential 
sources for horizontal transmission on poultry farms include old litter, untreated drinking 
water, other farm animals, domestic pets, wildlife species, house flies, insects, equipment and 
transport vehicles (113, 174, 196, 229, 245). Besides poultry meats, other major cause of 
human Campylobacter infection includes consumption of raw or unpasteurized milk, 
improperly/untreated water, and contacts with pets (7, 25, 75, 126, 225).  
 
Unlike Salmonella infection, the majority of Campylobacter infections in humans 
occur as sporadic cases; outbreaks of Campylobacter infection are rare (181, 184). Sporadic 
cases of Campylobacter infection have different epidemiological characteristics from 
outbreaks. Most outbreak cases of Campylobacter infection are associated with raw/ 
unpasterized milk and untreated/contaminated water (1, 33, 70, 184), while the majority of 
sporadic cases of Campylobacter enteritis result from the handling or consumption of 
undercooked poultry and/or other foods that are cross-contaminated with raw poultry meat 
during food preparation (7, 12, 31, 54, 108). The milk- and water- associated outbreaks 
usually occur in the spring and autumn and are uncommon in the summer, while sporadic 
Campylobacter infections often occur during summer (184). 
 
Although Campylobacter enteritis is the most common enteritis worldwide, the 
epidemiology of Campylobacter infections in developing countries is markedly different 
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from that in the developed countries (181). First, the incidence of campylobacteriosis in 
developing countries is much higher than in developed countries. Second, in developing 
countries, Campylobacter infection occurs mostly in the first few years after birth and 
declines with age. Most infections become asymptomatic among adults, presumably because 
of the acquisition of immunity due to multiple exposures to several serotypes of 
Campylobacter in the early stages of the life. In developed countries, infections can occur at 
any age and the infections are more severe. Inflammatory (bloody) diarrhea is more common 
among patients in developed countries. Third, the route of transmission in developing 
countries differs from that in developed countries. In developed countries, infections are 
often caused by uncooked food, while in developing countries, the presence of livestock in 
close proximity to living areas severely increases the risk of infection with Campylobacter. 
Fourth, in developed countries, Campylobacter infections typically increase during summer 
and fall. This seasonal variation is not significant in developing countries. 
 
3. Clinical Significance of Campylobacter Infections 
 
3.1 Campylobacter infection in human 
Campylobacter species, particularly C. jejuni and C. coli, have been recognized as 
important causes of bacterial enteric infections in humans since the late 1970’s (37). 
C. .jejuni and C. coli account for 85-95% and 5-15% of human campylobacteriosis, 
respectively (170). There is no difference between the characteristics of infections caused by 
C. jejuni and C. coli. The infectious dose for humans can be as low as 500 bacterial cells (32). 
The mean incubation period of the infections is 3.2 days which is longer than that of most 
other intestinal infections and the range can extend from 1-8 days (31, 32, 37). Infections 
with Campylobacter spp. are of variable severity ranging from asymptomatic to severe. The 
main clinical symptom of campylobacteriosis in humans is acute enteritis, which is 
characterized by acute diarrhea with abdominal cramps, fever, headache, and nausea. Some 
patients may also vomit. 
 
The symptoms of Campylobacter enteritis are different between developed countries 
and developing countries. Patients in developed countries usually have more severe 
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symptoms than those in developing countries (181). In developed countries, the common 
clinical features of Campylobacter spp. infection are acute gastroenteritis which is 
characterized by diarrhea, fever, and abdominal cramps (7). The diarrhea may range in 
severity from loose stools to profuse, watery stools with 10 or more bowel movements within 
one day (31). The initially watery diarrhea may develop into severe bloody diarrhea with 
fecal leucocytes as the disease progress. The acute diarrhea usually lasts 2-3 days, but it may 
persist for 1 week or longer particularly in patients with an acute colitis. Usually the 
gastroenteritis is self-limiting without the need for treatment (32). In developing countries, 
the typical clinical symptom is milder form of gastroenteritis which is usually characterized 
by watery, non-bloody, non-inflammatory diarrhea and symptomatic infections are extremely 
common in children younger than 2 years old (45, 127, 188). In contrast, in developed 
countries, infections occur in both adults and children. The highly endemic nature of 
infections in developing countries result in the early exposure to Campylobacter in life and 
increased Campylobacter-specific antibody levels with age which may account for the less 
severe clinical symptoms in adults. 
 
In some patients, the diarrhea is not significant, while acute abdominal pain is the 
predominant feature of Campylobacter infections. Since the abdominal pain is usually 
cramping in nature and most often occurs at the right lower quadrant of the abdomen, severe 
abdominal pain may mimic acute appendicitis which can lead to a mistaken diagnosis (7, 30-
32, 37).  
 
The symptoms of Campylobacter infection usually last for 3-4 days, and the disease 
gradually resolves over a week (32). A longer relapse may occur in 15-25% of affected 
patients who did not receive antibiotic treatment and last for several weeks (7, 31, 32). 
Patients may shed Campylobacter in their feces for several weeks after the clinical symptoms 
have disappeared unless treated with antibiotics (32). 
 
3.2 Campylobacter infection in animals 
 
In animals, C. jejuni and C. coli usually do not cause clinical diseases. They are 
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commensal inhabitants of the intestinal tracts of a wide range of domestic animals and pets, 
as well as wild animals and birds (12, 110, 234). Commercial poultry such as broilers, layers, 
turkeys, ducks and free-living birds are the natural reservoirs of C. jejuni and C. coli (220). 
Recent studies indicated that C. jejuni is increasingly associated with ovine abortions and it 
has replaced C. fetus as the predominant Campylobacter species causing sheep abortion in 
the United States (59, 213). 
 
3.3 Complications of Campylobacter infection in human 
 
In general, gastrointestinal complications due to Campylobacter infections rarely 
occur. However, Campylobacter spp. may spread from the gastrointestinal tract and lead to 
cholecystitis, pancreatitis, or massive gastrointestinal hemorrhage (7, 37). In addition to the 
gastrointestinal tract, Campylobacter also can cause some extraintestinal diseases, such as 
bacteremia, meningitis, endocarditis, septic arthritis, osteomyelitis and abortion (7, 32, 60). 
  
The most important post-infectious complication of C. jejuni infection is Guillain-
Barré Syndrome (GBS), an acute immune-mediated neuromuscular paralysis that may lead to 
respiratory muscle compromise and death (8, 131, 172). About 20 to 50% of patients with 
GBS symptoms have a preceding Campylobacter infection and symptoms of GBS typically 
start 1 to 3 weeks after a Campylobacter infection (26, 37). Althought C. jejuni infection is a 
common trigger of GBS, the risk of developing GBS after C. jejuni infection is actually quite 
low (172). Among the different C. jejuni strains involved with GBS, Penner serotype O:19 is 
most commonly associated with GBS in the United States (9, 172). It has been hypothesized 
that the molecular mimicry between the peripheral nerve gangliosides and sialylated 
Campylobacter lipooligosaccharide (LOS) may play a role in the pathogenesis of 
Campylobacter-induced GBS (131, 267). The antibodies induced by Campylobacter LPS 
cross-react to gangliosides, causing inflammation and tissue damage and eliciting the auto-
immune disease GBS (7, 26, 37, 132). 
 
4. Virulence and Pathogenesis of Campylobacter Infection  
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Although Campylobacter has emerged as a leading cause of bacterial food-borne 
illness during the past decade, relatively little is known of the molecular pathogenesis and 
virulence of Campylobacter infections compared to other enteric pathogens (127, 199, 247). 
This is partly due to the lack of an ideal animal model to evaluate the pathogenesis and 
virulence of Campylobacter (266). As a food-borne bacterial pathogen, Campylobacter 
enters the human body with food or water, survives the stomach acid and highly alkaline 
secretion from the bile duct, then colonizes the distal ileum and colon (109). Following 
colonization of the mucus blanket and adhesion to the intestinal cell surfaces, Campylobacter 
perturbs the normal absorptive capacity of the intestine by damaging epithelial cell function 
through direct cell invasion and/or toxin production, or indirectly by inducing host 
inflammatory reactions (260). Thus, factors involved in motility, intestinal adhesion, 
colonization, invasion, protein secretion, intracellular survival and toxin production are 
thought to be the major contributors to the pathogenicity of Campylobacter spp. Numerous 
studies using in vitro cell cultures and in vivo model systems have been performed to identify 
and characterize potential bacterial cell components involved in the pathogenesis of 
Campylobacter. In C. jejuni, the bacterial factors involved in disease pathogenesis include 
adhesins, flagella, capsular polysaccharides, cytolethal distending toxin (CDT) and many 
others. 
 
4.1 Adhesins 
 
The first step involved in Campylobacter colonization and pathogenesis is adherence 
to intestinal epithelial cells. The bacterial cell components involved in adhesion have been 
studied extensively using in vitro cell cultures and in vivo model systems. The adhesins 
identified in C. jejuni includes CadF, PEB1 (CBF 1), JIpA, and CapA. 
 
CadF (Campylobacter adhesion to fibronectin) binds specifically to fibronectin, 
which is located at the basolateral epithelial cells, and is required for maximal binding and 
invasion by C. jejuni (134, 167, 168). The binding of C. jejuni to immobilized fibronectin can 
be blocked by specific anti-CadF antibody (167). cadF mutants show a great reduction in 
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binding and invasion of INT407 cells and are unable to colonize chickens compared with 
wild-type isolates (167, 168, 273).  
 
PEB1 (CBF 1) is periplasmic and shares homology with the periplasmic-binding 
proteins of amino acid ATP-binding cassette (ABC) transporters involved in nutrient 
acquisition (78, 194). C. jejuni mutants that lack peb1 exhibit a reduction in the adherence to 
HeLa cells, as well as reduced colonization of mice when compared with wild-type isolates 
(194, 195).  
 
JlpA (C. jejuni lipoprotein A) is a surface-exposed lipoprotein that binds to Hsp90α 
on the surface of HEp-2 cells (115). Binding of JlpA to Hsp90α activates NF-κB and p38 
mitogen-activated protein kinase, which contribute to proinflammatory responses (194). 
Ablation of jlpA reduces C. jejuni adherence to HEp-2 cells by 18-19.4% compared to the 
wild-type strain (115). 
 
CapA is an autotransporter, and capA mutants show reduced adherence to Caco-2 
cells and decreased colonization and persistence in chickens (17). 
 
4.2 Flagella 
 
Flagella are the most extensively studied virulence determinant of Campylobacter. 
They are involved in several aspects of pathogenesis. Campylobacter have one or two 
unsheathed polar flagella. The unique characteristics of the flagellum, combined with the 
spiral shape of the bacterial cell, enable the organism to move using a darting motility. C. 
jejuni flagella and flagellar motility are vital to many aspects of C. jejuni pathogenesis, 
including host colonization, virulence in ferret models, protein secretion and host invasion. 
Numerous studies have shown that Campylobacter must be flagellated to colonize a host and 
cause disease (10, 92, 102, 133, 235, 254, 264). During the initial stages of infection, the 
flagella help Campylobacter overcome the clearing action of peristalsis and allow it to enter 
and cross the viscous mucosal layer covering the intestinal epithelia, where it adheres to the 
host cell surface.  
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Campylobacter flagellum is composed of two flagellin monomers, FlaA and FlaB, 
encoded by flaA and flaB respectively (95). The flaA and flaB genes are tandemly arranged in 
the Campylobacter genome and transcribed from σ28- and σ54-dependent promoters with its 
own promoter respectively (10, 95, 180, 235). The major subunit FlaA and the minor subunit 
FlaB share about 90% amino acide identity and are capable of assembling independently into 
functional filaments (95, 180, 235). Mutagenesis studies showed that a flagellar filament 
composed exclusively of the FlaA is indistinguishable in length from that of the wild type, 
but shows a slight reduction in motility, while the flagellar filament composed exclusively of 
the FlaB is severely truncated in length and greatly reduced in motility(95, 235). Thus, both 
FlaA and FlaB are required for full-length flagella expression and motility. Study by 
Wassenaar et. al. (254) demonstrated that mutants with reduced motility but intact FlaA can 
colonize chickens at levels similar to the parent strain; by contrast, mutants with full motility 
but inactivated flaA gene were significantly reduced in their ability to colonize chickens, 
which suggests the presence of FlaA, rather than motility, is necessary for optimal bacterial 
colonization of chicken intestine.  
 
Flagella also play an active role in the process of epithelia cell invasion. Mutagenesis 
and invasion studies showed the presence of a flagellum consisting of the FlaA protein is 
essential for invasion of INT-407 cells, whereas FlaB protein is not required (118, 235, 253). 
However, immotile mutants still penetrate at low levels, indicating that factors other than the 
flagella are also involved in invasion (265). 
 
In addition to a role in motility, C. jejuni flagella also serve as a type III secretion 
system (T3SS) to secrete both flagellar and non-flagellar proteins that contribute to cell 
adhesion and invasion (137, 208, 228). The protein CiaB (Campylobacter invasion-
associated antigen B) secreted by the flagellar secretion system is required for the invasion of 
INT-107 cells (135-137, 228). Disruption of ciaB reduces the colonization of C. jejuni in 
chicken (272). The mutation of FlaC which is also secreted by the flagellar secretion system 
affects Caco-2 cell invasion (228). 
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4.3 Lipooligosaccharide (LOS)/Capsular polysaccharides (CPS) 
 
LOS and CPS ( high molecular weight lipopolysaccharides) are common features on 
bacterial surfaces. Both LOS and CPS are the major surface antigens of Campylobacter and 
are highly variable among different Campylobacter strains (72, 122, 190). As mentioned 
earlier, the molecular mimicry between the Campylobacter LOS and human neuronal 
gangliosides is thought to lead to autoimmune disorders, including GBS (131, 267). 
 
Studies have shown that these surface polysaccharide molecules play important roles 
in the interaction of the bacteria with animal/human hosts and are required for cell invasion 
in vitro, chicken colonization, and full virulence in the ferret animal model (22, 23, 76, 118, 
120, 122, 161). Mutations in the genes involved in LPS synthesis and transport, such as galE, 
waaF and kpsE, significantly affect mutant cell adhesion to and invasion of INT-407 cells in 
vitro and increase sensitivity to some antibiotics compared that of the wild-type strain (76, 
120).  
 
4.4 Cytolethal distending toxin (CDT) 
 
One of the mechanisms involved in the virulence of Campylobacter is the production 
of toxins, which are important in diarrheal diseases. C. jejuni produces cytolethal distending 
toxin (CDT) (116), which is also produced by several other Gram-negative bacteria, 
including E. coli, Shigella, and Helicobacter (52, 117, 182). The action mechanism of CDT 
produced by C. jejuni is to cause sensitive eukaryotic cells to arrest at either the G1/S or 
G2/M transition of the cell cycle, depending on the cell type (100, 101, 141, 142, 256). 
 
The active holotoxin CDT consists of three subunits (CdtA, CdtB and CdtC) encoded 
by three adjacent or slightly overlapping genes cdtABC (41, 142). CdtB is the enzymatically 
active subunit of CDT and it shares homology with mammalian DNase I, however, CdtB has 
weak DNase activity in vitro (141). Whether DNA damage in vivo is a direct or indirect 
result of CdtB activity is still debatable (101, 159, 219, 248, 256). The exact function of 
CdtA and CdtC are unclear. Studies have shown both CdtA and CdtC can bind Hela cells 
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(146). It is suggested that CdtA and CdtC may mediate the binding and subsequent 
internalization of CdtB into the host cell (55, 142). 
 
The role of CDT in C. jejuni pathogenesis remains unclear. Studies showed that CdtA, 
CdtB and CdtC are all required for the induction of pro-inflammatory cytokine IL-8, a 
hallmark of C. jejuni pathogenesis (103) and CDT may have a role in eliciting inflammatory 
response in vivo (73). However, it seems that CDT is not required for colonization since 
mutants that lack CDT colonize chickens as well as wild-type strains (29).  
 
4.5 Glycosylation 
 
Campylobacter expresses two glycosylation systems: a general N-linked protein 
glycosylation pathway and an O-linked protein glycosylation pathway, which makes it 
unique in bacteria (23). Both of these pathways are important in intestinal colonization. 
 
The N-linked protein glycosylation pathway, which is encoded by a single gene 
cluster named pgl, is responsible for post-translational modification of asparagine residues on 
many surface proteins (23, 235). The N-linked glycan that is assembled by the Pgl system is 
conserved in all C. jejuni and C. coli strains that have been examined (23, 235, 248). 
Numerous studies haveshown that C. jejuni pgl mutants have significantly reduced ability to 
adhere to and invade host cells and colonize animal models; these studies have linked N-
linked protein glycosylation to bacterial virulence (23, 102, 119, 121, 125, 143). The pglH 
mutant of strain 81116 results in deficient glycosylation of a number of proteins and showed 
reduced adherence and invasion of human Caco-2 cells and colonization of chickens (121). 
An 81176 strain lacked glycoprotein Cj1469c was defective for both adherence to INT-407 
human epithelium cells in vitro and colonization of chicken gut (119).  
 
The O-linked protein glycosylation pathway is responsible for glycosylation of serine 
or threonine residues on flagellar proteins (23). O-linked glycosylation of flagellin is 
essential for the successful assembly of the flagellar filament (90). Defects in O-linked 
protein glycosylation result in the loss of motility, reduced adhesion and invasion of host 
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cells, and decreased virulence in ferret (96, 239). 
 
5. Clinical Treatment of Campylobacter Infection in Human 
 
Since the majority of Campylobacter infections are mild, self-limiting and usually 
resolve within a few days, no specific treatment is required for most patients with 
Campylobacter enteritis other than the oral replacement of fluid and electrolytes that are lost 
through diarrhea and vomiting (7, 32, 37). 
 
However, in specific clinical circumstances such as in severe infections (persistent 
high fever, bloody diarrhea, or more than eight bowel movements within one day), prolonged 
illness (clinic symptoms last longer than 1 week), or where the patient is pregnant, young, 
elderly, or has compromised immunity, antimicrobial treatment is usually warranted (7, 32, 
37).  
 
For clinical antibiotic treatment of confirmed Campylobacter infection, erythromycin 
(a macrolide) is the drug of choice because of its efficacy, safety, low cost and relatively 
narrow spectrum of activity (less inhibitory effect on fecal flora) (7, 31, 37, 67). In addition 
to erythromycin, fluoroquinolone (FQ) antimicrobials (e.g., ciprofloxacin) have been 
commonly used for the treatment of enteritis caused by Campylobacter because of their 
broad spectrum activity against enteric pathogens, especially when bacterial gastroenteritis is 
suspected and the cause of diarrheal illness has not yet been identified (7, 32, 37). However, 
the increasing prevalence of FQ-resistant (FQR) Campylobacter and macrolide-resistant 
Campylobacter has compromised the effectiveness of these treatments (67, 97, 110, 255). For 
serious systemic infection, tetracyclines and aminoglycosides, such as gentamicin, are the 
drugs of choice (32). Since up to 60% of strains may be resistant to tetracycline, care should 
be taken before prescribing this antibiotic (32). 
 
6. Antimicrobial Resistance of Campylobacter 
 
As mentioned in the previous section, FQ and macrolide antibiotics are the 
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antimicrobial agents considered for treatment of human Campylobacter enteritis when 
therapeutic intervention is needed (7, 45). In addition to use in human, these antibiotics have 
been used in animal husbandry for therapeutic purposes or as growth promoters (4). However, 
Campylobacter resistant to these clinically important antibiotics is increasingly prevalent, 
which is a major public concern. 
 
6.1 Action mode of antibiotics 
 
FQs, such as ciprofloxacin, enrofloxacin, and levofloxacin, are a class of structurally-
related synthetic antimicrobials that are effective against a wide range of Gram-positive and 
Gram-negative bacterial and are used in both treatment and prophylaxis of bacterial 
infections (16, 105, 107). FQs are bactericidal by inhibiting DNA synthesis. The main targets 
of FQs in bacteria are the type II topoisomerase DNA gyrases and/or topoisomerase IV (64, 
106). DNA gyrase catalyzes ATP-dependent negative supercoiling of DNA, which is an 
essential step in DNA replication, recombination, and transcription (42). Once inside 
bacterial cells, FQ antimicrobials form a stable complex with the target enzymes and trap the 
enzymes on DNA, resulting in double-stranded breaks in DNA and bacterial death (63, 223, 
242, 259). In Gram-negative bacteria, DNA gyrase is the primary target of FQ antibiotics, 
while topoisomerase IV is the main target of FQs in Gram-positive bacteria (106).  
 
Macrolides include erythromycin, tylosin, clarithromycin, azithromycin, and 
telithromycin, which have similar structures and are bacteriostatic agents that are active 
against most Gram-positive and some Gram-negative bacteria. They are important drugs for 
the treatment of upper and lower respiratory tract infections and gastric diseases caused by 
Helicobacter pylori and Campylobacter in humans (206, 268). Macrolides are protein 
synthesis inhibitors that reversibly bind to the 50S ribosome subunit and physically block 
tunnel entrance of the ribosome, causing the dissociation of peptidyl-tRNAs from the 
ribosome in the elongation cycle (86, 165, 186, 206, 242). 
 
Tetracyclines are an important class of antibiotics with a broad spectrum of activity, 
being active against many Gram-negative and Gram-positive bacteria and have been widely 
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used in both human and animal medicine (268). The tetracyclines can be divided into two 
groups, the atypical tetracyclines (e.g. anhydrotetracycline and 6-thiatetracycline) and typical 
tetracyclines (e.g. tetracycline and minocycline) (6, 48). The atypical tetracyclines function 
by disrupting bacterial membranes, whereas the typical tetracyclines are bacteriostatic and 
act on the ribosome as protein synthesis inhibitors. Once inside the bacteria cell, the 
tetracycline binds reversibly to the 30S subunit of the ribosome, which prevents the binding 
of the incoming aminoacyl-tRNA to the A site of the ribosome, resulting in elongation cycle 
halt and thus inhibition of nascent polypeptide synthesis (48, 69, 268).  
 
Aminoglycosides, such as streptomycin or gentamicin, are potent bactericidal 
antibiotics that have been widely used in human and animal medicine. The bactericidal 
activity of aminoglycosides is primarily exerted through irreversible binding of the 30S 
ribosome subunit, which interferes with the normal proofreading activity of the ribosome and 
prevents the translocation of the growing peptide from the A site to the P site of the ribosome 
(114, 156, 268). As a result, the elongation of nascent proteins is disrupted. 
 
6.2 Mechanisms of antibiotic resistance in Campylobacter 
 
6.2.1 FQ resistance 
 
 The dominant mechanisms involved in FQ resistance are 1) target ( DNA gyrase 
and/or topoisomerases IV) modification resulting in reduced affinity of these enzymes for 
fluoroquinolones, 2) reduced antibiotic intracellular accumulation by increasing efflux 
activity or decreasing outer membrane permeability, 3) reduced target enzyme expression, 
and 4) target protection mediated by the Qnr protein which can protect DNA gyrase from 
inhibition by the FQs (106, 192, 241). Of these resistance mechanisms, the first three are 
encoded by chromosomal elements, while the Qnr is encoded by a plasmid-carried 
quinolone-resistance gene and only confers a low level of resistance to FQs (192). In 
Campylobacter, the resistance to FQs is mediated by a point mutation in the quinolone 
resistance determining region (QRDR) of DNA gyrase subunit A (GyrA) (21, 81, 155, 192, 
268). No mutations in DNA gyrase subunit B (GyrB) have been involved in FQ resistance in 
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Campylobacter (21, 193, 198). Unlike the FQ resistance in other enteric organisms (e.g. 
Escherichia coli and Salmonella), acquisition of high-level FQ resistance in Campylobacter 
does not require stepwise accumulation of point mutations in gyrA. Instead, a single point 
mutation in the QRDR of gyrA is sufficient to lead to clinically relevant levels of resistance 
to FQ antimicrobials (72, 155, 210). The most commonly observed mutation in FQR isolates 
of Campylobacter is the C257T change in the gyrA gene which leads to the The-86-Ile 
substitution in the gyrase A subunit and confers high-level resistance to ciprofloxacin(155, 
268). Other mutations reported include Thr-86 Lys, Ala-70-Thr, and Asp-90-Asn, which are 
less common and only confer intermediate-level FQ resistance (67, 91, 155, 210, 252). 
Mutations in parC, which encodes topoisomerase IV, were reported to confer high-level FQ 
resistance (84); however, subsequent studies conducted by multiple independent investigators 
failed to identify the parC/parE gene in Campylobacter, which excluded the role of 
parC/parE mutations in Campylobacter resistance to FQ antimicrobials (21, 155, 193, 198). 
In addition to the mutations in the GyrA, the multidrug efflux pump also contributes to FQ 
resistance in Campylobacter. The main efflux pump involved in FQ resistance in 
Campylobacter is CmeABC, which is encoded by a three-gene operon (cmeA, cmeB, and 
cmeC) located on the Campylobacter chromosome. CmeABC functions as an energy-
dependent efflux system and contributes to both intrinsic and acquired resistance of C. jejuni 
to FQ antimicrobials (81, 147, 155, 204). CmeABC plays a major role in ciprofloxacin 
resistance in C. jejuni by reducing the accumulation of FQs in Campylobacter cells (81, 147, 
155). Thus, CmeABC functions synergistically with the gyrA mutations in mediating FQ-
resistance. All of the known FQ-resistance determinants in Campylobacter are 
chromosomally encoded, and plasmid-mediated quinolone resistance determinants, such as 
qnr, aac(6')-Ib-cr and qepA, have not been reported in Campylobacter (268). 
 
6.2.2 Macrolide resistance  
 
There are three mechanisms involved in macrolide resistance in bacteria: 1) 
modification of the antibiotic, 2) modification of the antibiotic target, and  3) drug efflux 
(144, 268). Target modification and active efflux are most commonly associated with 
macrolide resistance in Campylobacter (40, 83, 148, 157, 268). Enzyme-mediated target 
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methylation and inactivation of antibiotics have not been identified in C. jejuni or C. coli (86, 
268). 
 
The most common mechanisms for macrolide resistance in C. jejuni and C. coli are 
point mutations in domain V of the 23S rRNA target gene at positions 2074 and 2075, which 
correspond to positions 2058 and 2059, respectively, in E. coli (53, 148, 192, 268). So far 
A2074C, A2074G, A2074T, A2075G, A2075T, and A2075C mutations have been reported 
in erythromycin-resistant Campylobacter (268). Among these reported mutations, the 
A2074C, A2074G, and A2075G mutations all confer high-level resistance to macrolide 
antibiotics with erythromycin MIC > 128 µg/ml in C. jejuni and C. coli (38, 53, 83, 148, 157, 
268). But the A2075G mutation is the predominant mutation detected among the clinical- and 
field- isolated C. jejuni and C. coli (86, 138, 192). There are three copies of the 23S rRNA 
gene in the chromosome of Campylobacter and the resistance-associated mutations are 
usually identified in all three copies of the 23S rRNA gene (71, 191, 268). However, the 
wild-type and mutated alleles can coexist in some isolates and evidence suggests that at least 
two mutated copies are required to confer macrolide resistance (83, 148).  
 
In addition to the mutations in 23S rRNA, mutations affecting macrolide binding 
have also been identified in the ribosome protein L4 and L22 (40, 53). The G221A change in 
the L4 protein which leads to the Gly-74-Asp substitution and a insertion at position 86 or 98 
of the L22 protein can result in low levels of macrolide resistance in C. jejuni (40).  
 
As with FQ resistance, active efflux also contributes to macrolide resistance in 
Campylobacter (38, 40, 138, 148, 157, 268). Studies have shown that the CmeABC efflux 
pump contributes to both intrinsic and acquired resistance to erythromycin in C. jejuni and C. 
coli. Inactivation of CmeABC significantly reduced the MICs of macrolides in both the 
isolates with intermediate- or low-level resistance and the isolates with high-level resistance, 
which indicates that CmeABC functions synergistically with target mutations to confer 
resistance to macrolides in Campylobacter (40, 53, 87, 157). 
 
 
 
 
20 
6.2.3 Tetracycline resistance  
 
There are four mechanisms of tetracycline resistance: 1) efflux pumps that reduce 
drug accumulation, 2) protection of the ribosomal binding site of tetracycline by ribosomal 
protection proteins (RPPs), 3) drug modification, and 4) ribosomal modifications that alter 
the ability of the antibiotic to bind. In C. jejuni and C. coli, tetracycline resistance is mainly 
conferred through the ribosomal protection protein Tet(O) and the efflux pump CmeABC 
(268). The tet(O) gene is widespread in Campylobacter, and it is mainly encoded in 
transferable plasmids, but the gene located on chromosome has also been reported in 
tetracycline-resistant Campylobacter (56, 158, 169, 200, 238). Based on sequence homology, 
G+C content (40%), codon usage and Southern blot studies, it appears that Campylobacter 
acquired the tet(O) gene from Gram-positive bacteria through horizontal gene transfer (HGF) 
(27, 181, 237, 268). Studies have shown that Tet(O) recognizes an open A site on 
tetracycline-blocked ribosomal complexes and binds to the A site, which induces a 
conformational change in the region of the decoding site and results in the release of the 
bound tetracycline molecule. The conformational changes induced by the binding of the 
Tet(O) can persist after the release of the Tet(O), thus allowing the aa -tRNA to bind to the 
ribosomal A site (48, 49). Tet(O) functions synergistically with CmeABC to confer high-
level resistance to tetracycline (87, 147).  
 
6.2.4 Aminoglycoside resistance 
 
 Bacterial resistance to aminoglycosides is generally mediated by four mechanisms: 1) 
reduced accumulation of the drug in the intracellular environment, usually mediated by either 
increased efflux activity or by decreased outer membrane permeability, 2) 16S rRNA 
methylation that abolishes the intermolecular contacts between 16S rRNA and the drug, 3) 
ribosomal mutations that result in decreased affinity for the drug, and 4) enzymatic 
modification of the drug, one of the most important mechanisms of aminoglycoside 
resistance (114, 156, 268). Based on the type of reaction they catalyze, the intracellular 
aminoglycoside-modifying enzymes are classified into three different groups: 
aminoglycoside phosphotransferases, aminoglycoside adenyltransferases, and 
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aminoglycoside acetyltransferases (2, 6). The modifications mediated by these enzymes 
result in the loss of antibacterial activity of the drug due to abolished affinity for the bacterial 
ribosomal aminoacyl-tRNA site (150). So far only 3’ aminoglycoside phosphotransferases 
and aminoglycoside adenyltransferase have been described in Campylobacter; 3’ 
aminoglycoside phosphotransferases account for the majority of aminoglycoside-modifying 
enzymes in Campylobacter spp (85, 145, 187, 268). 
 
6.3 Emergence of antibiotic resistance in Campylobacter 
 
As mentioned in the previous section, target mutations are the major mechanisms by 
which Campylobacter develop resistance to FQs and macrolide antibiotics. Studies have 
shown FQR mutants emerge rapidly from a FQS population when treated with FQ 
antimicrobials (94, 155, 160, 217, 228, 244). Since there are different types of spontaneous 
point mutations that may occur in the QRDR region of the gyrA gene and different point 
mutations confer different levels of resistance to FQ antibiotics, the frequencies of 
emergence of FQR GyrA mutants range from approximately 10-6 to 10-8 in culture media, 
depending on the concentrations of ciprofloxacin used on the enumerating plates (263). The 
expression level of cmeABC also influences the frequencies of emergence of spontaneous 
FQR mutants and the same type of gyrA mutation confers different levels of resistance to FQs 
in different genetic background with varying levels of CmeABC expression (264). In 
chickens infected with FQS Campylobacter, treatment with enrofloxacin resulted in the 
emergence of FQR Campylobacter mutants, detected in feces within 24-48 hours after the 
initiation of treatment, and the FQR population continued to expand during the treatment and 
eventually occupied the intestinal tract at densities as high as 107 CFU/g feces (155, 160, 
244). Considering that FQs use in poultry promotes the development of FQR Campylobacter 
species in an originally FQS population and FQR Campylobacter can be transmitted to 
humans via the food chain, the Food and Drug Adminidtration (FDA) suspended all FQs use 
in poultry production in 2005 in the USA. Also FQR C. jejuni could develop in 
Campylobacter-infected patients treated with ciprofloxacin (66, 217, 261). These findings 
suggest that Campylobacter is highly mutable to FQs treatment. 
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In contrast to FQ resistance, there are several distinct features associated with 
erythromycin resistance development in Campylobacter. First, the spontaneous mutation 
rates for macrolide resistance are very low in Campylobacter (approximately 10-10) (148). 
Second, the development of macrolide resistance in Campylobacter is very slow. Treatment 
of chickens with therapeutic doses of tylosin in drinking water for a short time did not select 
for erythromycin-resistant mutants (139, 148) This finding is in clear contrast with the 
emergence of FQR mutant Campylobacter in poultry, which occurred in enrofloxacin-treated 
chickens rapidly after the initiation of treatment (155). However, erythromycin resistant 
mutants emerged in chickens after prolonged exposure to tylosin, which suggested that 
development of erythromycin-resistant mutants in Campylobacter need a prolonged exposure 
to macrolide (38, 148). Third, the mutants with low to intermediate levels (MIC = 8 to 64 
µg/ml) of resistance to erythromycin harbor mutations different from those found in high-
level erythromycin-resistant mutants. Low-level erythromycin-resistant Campylobacter have 
mutations in the L4 and L22 proteins or no detectible mutations at all, which are not stable in 
the absence of macrolides.  The high-level erythromycin resistant mutants (MIC ≥ 512 µg/ml) 
usually harbor a specific point mutation in the 23S rRNA gene, and most of these 23S rRNA 
mutations can be stably maintained in the absence of macrolide antibiotics (38, 129, 148). 
Fourth, although macrolide resistance is generally more prevalent in C. coli isolates than in C. 
jejuni isolates, studies have shown there is no significant difference in the frequencies of 
emergence of erythromycin-resistant mutants between these two strains, suggesting that C. 
coli is not intrinsically more mutable then C. jejuni with regard to developing macrolide 
resistance (148). 
 
6.4 Prevalence of antibiotic resistant Campylobacter 
 
Owing to the widespread use of these antibiotics in both animals and humans, a rapid 
increase in the proportion of Campylobacter strains resistant to antimicrobial agents has been 
reported all over the world , which has become a major public health concern in recent years 
(6, 67, 97, 111, 169, 173, 255).  
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The emergence of FQR Campylobacter strains was first noticed in the early 1990s 
after the approval of the use of FQs in animal production (169). In countries where FQs have 
been licensed for animal use, there were increased rates of isolation of FQR Campylobacter 
strains in both humans and animals following the licensure (169). Many publications have 
shown that the use of FQs in poultry and livestock is associated with increased FQR strains in 
humans (173, 205, 211, 227, 246).  
 
In the United States, there were no reports of FQR Campylobacter strains isolated 
from humans before 1992. However, several recent studies showed that about 19%-40% of 
Campylobacter strains isolated from humans were resistant to ciprofloxacin (97, 173). In 
Canada, no FQR Campylobacter strains were isolated during 1980-1986, but recent reports 
indicated that ciprofloxacin resistance among C. jejuni has dramatically increased since 1992 
and reached 47% in 2001 (79, 80). In Europe, there is also a clear tendency of emerging FQs 
resistance in Campylobacter and the rate of FQ resistance has rapidly increased in the last 
decade (6, 32, 77, 98, 152, 153, 169, 189, 197). In Asia, studies showed that FQR 
Campylobacter strains isolated from humans increased rapidly since 1993 and the FQ 
resistance rates have reached more than 80% in Thailand, Taiwan, and Hong Kong (44, 111, 
240). In contrast, although FQ resistance in Campylobacter isolates was also been observed 
in Australia and New Zealand, the rate of FQR Campylobacter isolates in these regions was 
much lower than that from the other regions (6, 61, 88, 222). The lack of FQs use in 
veterinary medicine probably accounts for the low frequency of FQ resistance in these 
regions.  
 
Since the 1990s, an increase in the prevalence of macrolide resistance among C jejuni 
and C. coli has also been reported in both developed and developing countries (20, 24, 28, 67, 
86, 211), but the rate of macrolide resistance among Campylobacter is highly variable among 
different countries (13, 67, 68, 99, 104, 112, 166, 178, 212, 218). In Spain, resistance to 
macrolide has been reported to be as high as 90%, but trends over time for macrolide 
resistance show stable and low rates in countries such as Japan, Sweden, and Finland (99, 
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112, 178, 185, 212). Several studies showed that resistance to macrolides is more prevalent in 
C. coli than C. jejuni in both human and animal isolates (67, 188). 
 
6.5 Fitness of antibiotic resistant Campylobacter 
 
Several studies have shown that FQR Campylobacter mutants carrying gyrA 
mutations can be stably maintained in the absence of antibiotic selection pressure and FQR 
Campylobacter continue to persist on poultry farms even after FQs withdrawal (15, 202, 203). 
The persistence of FQR Campylobacter in the absence of antibiotic selection pressure may be 
due to the enhanced fitness of the FQR Campylobacter. Recently Luo et al. examined the 
persistence and biological fitness of FQR Campylobacter harboring the Thr-86-Ile mutation 
in GyrA in chickens in the absence of antibiotic selection pressure by using in vivo-derived, 
clonally-related isolates and defined isogenic mutants (154). Results from this study showed 
that when mono-inoculated into chickens, both FQR and FQS strains were able to colonize 
and persist in chickens with equal efficiency in the absence of antibiotic usage. When co-
inoculated into chickens as a pairwise competition, the FQR Campylobacter outcompeted the 
FQS Campylobacter and quickly became the dominant population in the chicken host in the 
majority of pairs, which indicated that acquisition of FQR mutants carrying the Thr-86-Ile 
mutation in GyrA enhances the in vivo fitness of FQR Campylobacter instead of causing a 
fitness burden. And the prolonged colonization (upto 3 months) in vivo did not result in the 
loss of the resistance phenotype and the reversion/loss of the specific resistance associated 
mutation in GyrA (154, 269). Since there are no compensatory mutations in GyrA and GyrB, 
which are the targets of FQ antimicrobials in Campylobacter, the enhanced fitness likely is 
likely due to the effect of the C257T mutation in gyrA.  
 
For erythromycin-resistant Campylobacter, there is no published information about 
the ecological fitness of the resistant mutants. One study in Denmark showed the reduction in 
tylosin usage as a growth promoter in pigs has led to a significant reduction in the occurrence 
of erythromycin-resistant C. coli isolated from pigs (3).  
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7. Prevention and Control  
 
7.1 Control of Campylobacter on poultry farms  
 
Since poultry is the major reservoir of Campylobacter and contaminated poultry meat 
is considered as an important source for human campylobacteriosis, reduction of 
Campylobacter contamination in poultry would have an important impact on human public 
health. It is not effective to control Campylobacter during processing because of the high 
prevalence of Campylobacter in poultry flocks. Therefore, control of Campylobacter 
infection in poultry farm should start from the preharvest stage (249). Currently, two major 
strategies have been used for control and prevention of Campylobacter infection at the farm 
level: 1) biosecurity to eliminate Campylobacter from the farm; and 2) reduction/prevention 
of Campylobacter colonization by competitive exclusion, phage treatment, and vaccination 
(57, 151, 175, 250, 251). 
 
7.1.1 Biosecurity  
 
Since external environmental contamination during the life of the flocks is likely to 
be the primary source of Campylobacter infection, strict hygiene and biosecurity measures 
have been used in an attempt to control Campylobacter infections in chicken flocks (12, 82, 
245). Empiricial biosecurity measures to prevent Campylobacter colonization of poultry 
flocks include use of an all-in all-out policy, cleaning and disinfection of buildings between 
flocks, maintaining buildings in good condition, controlling and keeping buildings free of 
vermin and wild birds, restricting other domestic animals on the farm, proper disposal of 
dead birds, along with change and disinfection of boots and outer protective clothing for 
workers, restriction on staff and equipment entering broiler house, and chlorination of 
drinking water (175). However, intensifying biosecurity can only reduce the colonization 
level or delay the onset time of colonization of birds by Campylobacter, but can not eliminate 
the introduction of Campylobacter into broiler flocks (175, 220, 249).  
 
Because Campylobacter are commonly present in the poultry farm environment and 
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poultry flocks can be infected by multiple sources, it is unlikely that flock exposure to 
Campylobacters can be prevented by use of strict biosecurity measures alone (175, 176). In 
addition, stringent biosecurity measures are expensive and difficult to maintain (151). 
Therefore, other supportive measures, such as competitive exclusion (CE), phage treatment, 
antibacterial agents and vaccination, have also been explored.  
 
7.1.2 Competitive exclusion (CE) 
 
With CE, defined or undefined gut flora or probiotic anaerobic bacteria is used to 
prevent target bacteria colonization. It is thought that CE works through the generation of 
bactericidal metabolites, such as organic acids, or though nutritional competition. Although 
CE has been developed as a successful approach for the control of organisms like Salmonella, 
its efficacy for Campylobacter is variable and unpredictable (163, 177, 215, 216, 249). Some 
studies showed that CE could help reduce the colonization level and prevalence of 
Campylobacter in broilers, but in other experiments, these CE materials had no effect (5, 164, 
177, 215, 216, 249). Since CE materials are derived from live adult birds, it is not surprising 
that they are inconsistent and are influenced by the status of the donor birds and the site from 
which the materials are collected (140, 164, 175, 215, 216). Recently, studies showed that 
when given as feed supplements, bacteriocins extracted from Bacillus circulans, 
Paneibacillus pylomyxa and Lactobacillus salivarius were highly effective in eliminating 
Campylobacter colonization from broilers and young commercial turkeys (46, 232, 233). 
Several probiotics from Saccharomyces boulardii, Lactobacillus acidophilus and 
Streprococcus faecium have been found to be able to partially reduce Campylobacter 
colonization in broiler chickens under laboratory conditions (43, 149, 171). Even though 
these CE materials seem to work under experimental conditions, their abilities to control and 
prevent Campylobacter colonization in chickens under production conditions remain to be 
investigated. Currently none of the commercially available CE materials appear to be 
effective in excluding Campylobacter from broiler flocks under production conditions (162). 
 
7.1.3 Vaccination 
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Since Campylobacter-specific antibodies can effectively reduce Campylobacter 
colonization of chickens (57, 243), vaccination seems to be a feasible approach for control 
and prevention of Campylobacter. Several vaccine development strategies are currently 
being investigated. These reported immunization studies have used killed whole-cell 
vaccines, flagellin-based vaccines, or genetically engineered live vectors expressing 
Campylobacter-specific antigens. The protective effect of these vaccines against 
Campylobacter was variable. In general, the studies suggest that the Campylobacter-specific 
antibodies generated provide some, but not biologically significant protective effects in 
chickens (39, 57, 128, 179, 207, 249, 250, 257, 258, 271). However, a recent study reported 
that oral immunization of chickens with an avirulent Salmonella strain expressing the C. 
jejuni CjaA antigen (the substrate-binding component of an ABC transport system) 
drastically reduced the colonization of Campylobacter in the majority of birds upon 
homologous challenge (262). The encouraging results from this study suggest the possibility 
of using CjaA protein in combination with the attenuated Salmonella vector as a protective 
vaccine against Campylobacter colonization in poultry. Passive immunization by oral 
administration of anti-Campylobacter antibodies has also been reported to have both 
therapeutic and prophylactic properties in chickens (231, 243, 249). Therefore, it may be 
possible to immunize parent flocks to produce passively protected offspring. Overall, the 
limited results from the experimental vaccines suggest that vaccination may be a feasible 
strategy to control Campylobacter infection on poultry farms. 
 
7.1.4 Phage therapy 
 
Bacteriophages are viruses that can infect, multiply, and kill susceptible bacteria. Like 
most bacterial species, Campylobacters also have their own specific bacteriophages. 
Campylobatcer-specific bacteriophages can be readily isolated from broiler chickens and the 
farm environment (19, 50, 51, 65, 151, 251). Bacteriophages have shown to be a promising 
approach to reduce Campylobacter colonization in broilers, but currently no commercial 
product is available. Recent studies showed that bacteriophages significantly reduce the 
Campylobacter number in both therapeutic and preventive treatment of chickens with 
Campylobacter-specific bacteriophage. However, the level of reduction was variable and was 
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affected by many factors, such as bacteriophage type, dosage, bacteriophage dynamics and 
bacteriophage ecology in chickens. More work will be needed to determine if phage therapy 
is an effective and/or practical biological control measure for the reduction of Campylobacter 
in poultry. 
 
7.1.5 Other strategies 
 
Other intervention strategies that may be used on poultry farm to control and prevent 
Campylobacter colonization in broiler flocks include use of inbred chicken lines, which are 
resistant to cecal colonization by Campylobacter (35, 230) or supplementation of feed with 
prebiotics (e.g. fructoologosaccharide, lactose, mannose-oligosaccharide), immune response 
stimulators (e.g. selenium, beta-glucan), antimicrobials (e.g. salinomycin, flavophopholipol), 
or active charcoal (14, 34, 62). Similar to the strategies mentioned previously, these 
strategies have shown limited success in reducing the incidence of Campylobacter 
colonization in chickens.  
 
7.2 Control of Campylobacter at the slaughterhouse during processing 
 
Multiple measures in the slaughterhouse have been explored to reduce carcass 
contamination by Campylobacter during slaughter. Currently, the most promising control 
strategy is the separation of Campylobacter-positive and Campylobacter-negative flocks 
during slaughter (“scheduled processing”) and decontamination of the meat from positive 
flocks (250). However, one issue of the scheduled processing is the sensitivity of the on-farm 
test. False-negative tests would result in misidentification of positive flocks which would be 
treated as safe meat. The feasibility of scheduled processing remains an issue to the poultry 
industry (249).  
 
In addition being used to reduce Campylobacter colonization in live poultry, 
bacteriophages have also been used as a disinfection agent for poultry meat in processing 
facilities. Several studies investigating the direct application of bacteriophages onto raw 
chicken skin showed a significant decrease in Campylobacter numbers on the surface of 
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experimentally-contaminated chicken skin (18, 89). However, these studies only involved 
experimentally-infected chickens and only showed efficacy in the laboratory. Additional 
studies are needed to assess the possibility of using bacteriophage to control natural 
contaminants and improve food safety in a real-life setting (93). 
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1. Abstract 
 
Campylobacter jejuni is a major foodborne pathogen and a common causative agent 
of human enterocolitis. Fluoroquinolones are a key class of antibiotics prescribed for clinical 
treatment of enteric infections including campylobacteriosis, but fluoroquinolone-resistant 
Campylobacter readily emerges under the antibiotic selection pressure. To understand the 
mechanisms involved in the development of fluoroquinolone-resistant Campylobacter, we 
compared the gene expression profiles of C. jejuni in the presence and absence of 
ciprofloxacin using DNA microarray. Our analysis revealed that multiple genes showed 
significant changes in expression in the presence of a suprainhibitory concentration of 
ciprofloxacin. Most importantly, ciprofloxacin induced the expression of mfd, which encodes 
a transcription-repair coupling factor involved in strand-specific DNA repair. Mutation of the 
mfd gene resulted in approximately 100-fold reduction in the rate of spontaneous mutation to 
ciprofloxacin resistance, while overexpression of mfd elevated the mutation frequency.  In 
addition, loss of mfd in C. jejuni significantly reduced the development of fluoroquinolone-
resistant Campylobacter in culture media or chickens treated with fluoroquinolones. These 
findings indicate that Mfd is important for the development of fluoroquinolone resistance in 
Campylobacter, reveal a previously unrecognized function of Mfd in promoting mutation 
frequencies, and identify a potential molecular target for reducing the emergence of 
fluoroquinolone–resistant Campylobacter. 
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2.  Author Summary 
 
As a foodborne bacterial pathogen, Campylobacter jejuni is a common causative 
agent of gastrointestinal illnesses in humans. Development of antibiotic resistance in 
Campylobacter, especially to fluoroquinolone (a broad-spectrum antimicrobial), 
compromises clinical treatments and presents a major public health threat. It is poorly 
understood why Campylobacter is highly adaptable to fluoroquinolone treatment and how it 
acquires mutations associated with fluoroquinolone resistance. Understanding the molecular 
mechanisms involved in the resistance development will help us to reduce the emergence of 
FQ-resistant Campylobacter. Using DNA microarray and other molecular methods as well as 
animal studies, we uncovered the key role of Mfd in promoting spontaneous mutations and 
development of fluoroquinolone resistance in Campylobacter. Mfd is a transcription-repair 
coupling factor involved in DNA repair and was not previously known for its role in 
promoting mutations conferring antibiotic resistance. Our findings not only reveal a novel 
function of Mfd, but also provide a potential molecular target for reducing the emergence of 
fluoroquinolone-resistant Campylobacter. 
 
3. Introduction 
 
Campylobacter jejuni, a Gram-negative microaerobic bacterium, is one of the most 
prevalent bacterial foodborne pathogens in humans, causing more than 2 million cases of 
diarrhea each year in the U.S. alone [1, 2, 3]. As an enteric pathogen, this organism causes 
watery diarrhea and/or hemorrhagic colitis. Campylobacter infection is also the most 
common antecedent to Guillain-Barre syndrome, an acute flaccid paralysis that may lead to 
respiratory muscle compromise and death [4, 5]. In developed countries, person-to-person 
transmission of Campylobacter is rare, and the main source of human Campylobacter 
infections is via food, water, or milk contaminated by Campylobacter [6].  
 
Fluoroquinolone (FQ) antimicrobials are often prescribed for clinical treatment of 
diarrhea caused by enteric bacterial pathogens including Campylobacter [7, 8]. However, 
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Campylobacter is increasingly resistant to FQ antimicrobials, which has become a major 
concern for public health [9, 10, 11]. FQ-resistant (FQR) Campylobacter developed in food 
producing animals can be transmitted to humans via the food chain. Poultry are considered 
the major reservoir for C. jejuni and a significant source for FQR Campylobacter infections in 
humans, because the majority of domestically acquired cases of human campylobacteriosis 
result from consumption of undercooked chicken or food contaminated by raw chicken [2, 12, 
13]. Although FQ antimicrobials have been banned since 2005 in poultry production in the 
U.S., FQR Campylobacter continue to persist on poultry farms [14, 15, 16].  
 
The main targets of FQs in bacteria are DNA gyrases and/or topoisomerase IV [17, 
18]. In Campylobacter, the resistance to FQ antimicrobials is mediated by point mutation in 
the quinolone resistance-determining region (QRDR) of gyrA in conjunction with the 
function of the multidrug efflux pump CmeABC [10, 19, 20, 21]. Acquisition of high-level 
FQ resistance in Campylobacter does not require stepwise accumulation of point mutations 
in gyrA. Instead, a single point mutation in gyrA can lead to clinically relevant levels of 
resistance to FQ antimicrobials [19, 20, 22]. Specific mutations at positions Thr-86, Asp-90 
and Ala-70 in GyrA have been linked to FQ resistance in C. jejuni [10, 19]. When 
enumerated by ciprofloxacin (CIPRO)-containing plates, spontaneous FQR Campylobacter 
mutants occur at a frequency as high as 10-6 [23], suggesting that C. jejuni possess a high 
mutation rate to FQ resistance. CmeABC, an energy-dependent efflux system, contributes 
significantly to the intrinsic and acquired resistance to FQs in C. jejuni by reducing the 
accumulation of the antibiotics within Campylobacter cells [19, 20, 24, 25]. The expression 
level of cmeABC also influences the frequencies of emergence of spontaneous FQR mutants 
[23]. 
 
One unique feature of FQ resistance development in Campylobacter is the rapid 
emergence of FQR mutants from a FQ-susceptible (FQS) population when treated with FQ 
antimicrobials. This has been observed in Campylobacter-infected animals or patients treated 
with FQs [19, 26, 27, 28, 29, 30]. In chickens infected with FQS Campylobacter, treatment 
with enrofloxacin resulted in the emergence of FQR Campylobacter mutants that were 
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detected in feces within 24-48 hours after the initiation of treatment, and the FQR population 
continued to expand during the treatment and eventually occupied the intestinal tract at a 
density as high as 107 CFU/g feces [19, 29, 30]. As shown in a comparison study, the same 
FQ treatment did not result in the development and enrichment of FQR E. coli in chickens 
[29], suggesting that C. jejuni has a unique ability to adapt to FQ treatment. This high 
frequency of emergence of FQR Campylobacter mutants in response to the selection pressure 
may have directly contributed to the global prevalence of FQR Campylobacter. For example, 
multiple studies have shown the temporal link between the approval of FQ antimicrobials for 
use in animal production and the rapid increase of FQR Campylobacter isolates from both 
animals and humans [9, 31, 32, 33, 34, 35, 36, 37, 38, 39]. In some regions of the world, the 
vast majority of Campylobacter isolates have become resistant to FQ antimicrobials [22, 40, 
41].  
 
The rapidness and magnitude of FQ resistance development in Campylobacter in 
response to FQ treatment suggest that both selective enrichment of pre-existing spontaneous 
mutants and adaptive gene expression may contribute to the emergence of FQR 
Campylobacter, but how Campylobacter responds to FQ treatment is unknown. Within 
bacterial cells, FQ antimicrobials form a stable complex with gyrases and DNA, which 
generates double-stranded breaks in DNA and leads to bacterial death [18]. In other bacteria, 
antibiotic treatments (including FQs) induce the SOS response, which upregulates multiple 
genes involved in DNA repair, recombination, and mutation as well as other functions 
[42,43,44,45]. The SOS response is controlled by LexA, a transcriptional repressor. DNA 
damage triggers LexA autocleavage, which derepresses the SOS genes controlled by LexA. 
Once activated, SOS response promotes the development of drug resistance, horizontal 
transfer of genetic materials, and production of virulence factors [45, 46, 47]. Unlike many 
other bacterial organisms, epsilonproteobacteria including Campylobacter and Helicobacter 
do not have a LexA ortholog [46] and also lack many genes involved in DNA repair, 
recombination, and mutagenesis, such as the mutHL genes (methyl-directed mismatch repair), 
the umuCD genes (UV-induced mutagenesis), and SOS-controlled error-prone DNA 
polymerases [48, 49, 50]. These observations suggest that Campylobacter may not have the 
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typical SOS response system. In light of this possibility, it is intriguing to determine how 
Campylobacter copes with FQ treatment and what facilitates the emergence of FQR mutants 
in Campylobacter.  
 
In this study, we examined the gene expression profiles of C. jejuni NCTC 11168 in 
response to treatment with CIPRO. Consistent with the prediction, a typical SOS response 
was not observed in Campylobacter treated with CIPRO. However, 45 genes showed ≥1.5-
fold (p < 0.05) changes in expression when Campylobacter was exposed to a suprainhibitory 
dose of CIPRO for 30 min. One of the up-regulated genes was mfd (mutation frequency 
decline), which encodes a transcription-repair coupling factor involved in DNA repair. The 
mfd gene in E. coli was originally linked to the phenotype of mutation frequency decline [51, 
52]. Subsequently it was found that Mfd functions as a transcription-repair coupling factor 
and promotes strand-specific DNA repair [53, 54]. DNA lesions stall RNA polymerase 
during transcription. Mfd displaces the stalled RNA polymerase from the DNA lesions in an 
ATP-dependent manner, recruits the UvrABC excinuclease complex, and enhances the repair 
of the DNA lesions on the transcribed strand [54, 55]. Thus, Mfd couples transcription with 
DNA repair and contributes to mutation frequency decline. Recently it was reported that 
depending on the nature of DNA damage and the availability of NTPs, Mfd can also promote 
the forward translocation of arrested RNA polymerase in the absence of repair, leading to 
transcriptional bypass of non-repaired lesions [55]. In contrast to its previously known 
function in the decline of mutation frequency in other bacterial organisms [51, 52], Mfd in 
Campylobacter was found to promote the emergence of spontaneous FQR mutants and the 
development of FQR mutants under FQ treatments in this study. These findings define a 
novel function of Mfd and significantly improve our understanding of the molecular 
mechanisms underlying the development of FQR Campylobacter. 
 
4. Results 
 
Transcriptional analysis of C. jejuni response to FQ treatment  
 
To understand the adaptive response of Campylobacter to FQ treatment, DNA 
microarray was used to analyze the transcriptional changes in C. jejuni NCTC 11168 after 
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exposure to CIPRO. When the Campylobacter cells were treated with a subinhibitory 
concentration (0.06 µg/ml; 0.5 x the MIC) of CIPRO for 1.5 hours, no genes showed ≥1.5-
fold changes in expression, suggesting that the transcriptional response to the low dose of 
CIPRO was very limited. When the Campylobacter cells were treated with a suprainhibitory 
concentration (1.25 µg /ml; 10 x the MIC) of CIPRO for 30 min, 45 genes showed ≥1.5-fold 
(p < 0.05) changes in expression (Table 1), among which 13 were up-regulated and 32 were 
down-regulated. The up-regulated genes are involved in cell membrane biosynthesis, cellular 
processes, and transcription-coupled DNA repair or have unknown functions, while the 
majority of the down-regulated genes are involved in energy metabolisms (Table 1). 
Consistent with the lack of LexA, the core genes involved in SOS responses in other bacteria, 
such as recA, uvrA, ruvC, ruvA, and ruvB, did not show significant changes in expression. 
The expression of other genes involved in DNA repair and recombination also did not change 
significantly. These findings indicate that C. jejuni does not mount a typical SOS response or 
upregulate the general DNA repair system in the early response to CIPRO treatment. Notably, 
cj1085c, a homolog of mfd, was upregulated in the presence of CIPRO. Two up-regulated 
genes, uppP and uppS, encode products involved in cell wall production [56,57], while pldA 
encodes an outer membrane phospholipase that has been implicated in hemolysis, capsular 
production, and virulence [58, 59]. According to the Q values, the identified genes would 
have an estimated false discovery rate (FDR) of 20%. However, quantitative real-time RT-
RCR (qRT-PCR) confirmed all of the 11 genes selected from the microarray list (Table 1), 
suggesting that the actual FDR is lower than the estimation.  
 
Characteristics of Mfd  
 
Cj1085c (978aa) was annotated as Mfd [48] and shows 31.5% amino acid identity to 
the E. coli Mfd protein (1148 aa). In addition, it contains the characteristic domains 
conserved in Mfd proteins, such as the ATP/GTP-binding site motif and the superfamily II 
helicase motif. Mfd in other bacteria has been shown to be involved in strand-specific DNA 
repair by displacing lesion-stalled RNA polymerase and recruiting enzymes involved in 
recombination events [54,60]. The mfd locus is highly conserved in Campylobacter and is 
present in all Campylobacter species and C. jejuni strains that have been sequenced to date. 
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The Mfd proteins in different Campylobacter species share 57-79% identity to the Mfd in C. 
jejuni NCTC 11168. Within C. jejuni, the Mfd proteins are 98-100% homologous among 
different strains. The mfd gene is located in the middle of a gene cluster, whose transcription 
is in the same direction (partially shown in Fig. 1A). The downstream gene Cj1084c encodes 
a putative ATP/GTP binding protein, while the upstream gene Cj1086c encode a hypothetical 
protein [48]. It is unknown if mfd and its flanking genes form an operon, but it appeared that 
Cj1086c and mfd were co-transcribed because a RT-PCR product spanning both ORFs was 
amplified (data not shown).  
 
Expression levels of mfd influence the frequency of emergence of spontaneous FQ-
resistant mutants.  
 
Since mfd was the only DNA repair related gene that showed a significant change in 
expression in the early response of C. jejuni to CIPRO treatment (Table 1), we examined its 
role in the emergence of spontaneous FQR mutants in Campylobacter. Firstly, the mfd gene 
was inactivated by insertional mutagenesis (Fig. 1B). As shown in Fig. 2, the mfd mutant 
(JH01) showed a approximately 100-fold reduction in the frequencies of emergence of 
spontaneous FQR mutants detected using plates containing three different concentrations (1, 2, 
and 4 µg/ml, respectively) of CIPRO. Complementation of the mfd mutant in trans by a 
plasmid-carried mfd restored the frequencies of mutant emergence to the wild-type level 
(JH02 in Fig. 2). As determined by qRT-PCR, the expression level of mfd in the 
complemented construct (JH02) was fully restored (1.7 x the wild-type level). pRY112 alone 
(without the cloned mfd gene) did not complement the mfd mutant in the mutation frequency 
(data not shown). These results indicate that Mfd contributes significantly to the rate of 
spontaneous mutations to FQ resistance. 
 
Secondly, we determined if the enhanced expression of mfd increases the mutation 
frequency. For this purpose, we constructed strain JH03, which was a wild-type 11168 strain 
containing an extra copy of mfd carried on a shuttle plasmid. In JH03, the mRNA of mfd 
increased 3.8 times compared with that in 11168 as determined by qRT-PCR. When 
compared with the wild-type 11168, the frequency of emergence of FQR mutants from JH03 
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increased about 10-fold (Fig. 2). The increase was reproducible in multiple experiments and 
was statistically significant (P < 0.05). These results indicated that overexpression of mfd 
increases the frequency of emergence of spontaneous FQR mutants. 
 
Given that there is only one nucleotide between the mfd gene and its downstream 
gene cj1084c, it was prudent to determine if the mfd mutation resulted in a polar effect on the 
expression of cj1084c. RT–PCR showed that cj1084c was transcribed at a comparable level 
in both the mfd mutant and the wild-type NCTC 11168 (Fig. 1C). RT-PCR was also 
performed using 10-fold serial dilutions of the RNA template, which yielded comparable 
results between the two strains (data not shown). PCR without the reverse transcriptase did 
not yield a product (Fig. 1C), indicating that the mRNA templates had no DNA 
contamination. These results suggested that the insertional mutation in the mfd gene did not 
cause an apparent polar effect on expression of the downstream gene. This finding plus the 
complementation data (Fig. 2) strongly indicate that loss of Mfd is responsible for the 
observed reduction in the mutation frequency in JH01. 
 
Loss of mfd does not affect the susceptibility of C. jejuni to antibiotics. 
 
To examine if the reduction in the emergence of spontaneous FQR mutants is caused 
by the increased susceptibility of the mfd mutant to CIPRO, we compared the MICs of 
several antibiotics in the mfd mutant with those in the wild type. Our results did not reveal 
any differences between the mutant and the wild type in their susceptibility to the tested 
antibiotics including erythromycin, ampicillin, streptomycin, and CIPRO (data not shown). 
In addition, there was no apparent difference in growth kinetics between the wild-type and 
the mfd mutant either in MH broth (without antibiotics) or in MH broth supplemented with a 
subinhibitory concentration (0.06 µg/ml) of CIPRO (Fig.3). The growth rates of the mfd 
over-expressing strain (JH03) and the complemented mutant (JH02) were also similar to that 
of the wild type (Fig. 3). Thus, the reduced spontaneous mutation rate to FQ resistance in the 
mfd mutant was not attributable to decreased growth rate or increased susceptibility to 
antibiotics. In addition, the CIPRO-resistant colonies examined for gyrA mutations all carried 
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the C257T mutation in gyrA and had a CIPRO MIC of > 32 µg/ml regardless of the 
backgrounds (11168 or JH01) from which the mutants were selected. 
 
Mfd contributes to the emergence of FQR Campylobacter under in vitro treatment 
 
FQR Campylobacter mutants emerge rapidly from a FQ-susceptible population once 
treated with FQ antimicrobials [19,26,27,28,29,30]. To determine if Mfd influences the 
development of FQR Campylobacter under selection pressure, we conducted in vitro growth 
experiments, in which C. jejuni was treated with a suprainhibitory concentrations of CIPRO 
(4 µg/ml). In the first treatment experiment, 109 CFU of bacterial cells were inoculated into 
each flask containing 100 ml MH broth with 4 µg/ml of CIPRO, yielding an initial cell 
density of 107 CFU/ml. At the beginning of the treatment, 1-3 CFU/ml of FQR mutants were 
detected in the flasks inoculated with 11168, while no FQR mutants were detected in the 
cultures inoculated with JH01 (Fig. 4A). One day after the initiation of the treatment, the 
numbers of FQR mutants in the 11168 cultures grew to a level ranging from a few hundreds 
to a few thousands CFU/ml, while no mutants or about 1 CFU/ml of FQR mutants were 
detected in the cultures of JH01 (Fig. 4A). The FQR populations expanded on day 2 in both 
strains, but the FQR population of JH01 was still about 1,000-fold less than that of 11168. 
Due to the continued enrichment of the FQR mutants by CIPRO and the fact that the mutants 
of 11168 was entering the stationary phase, the average difference between 11168 and JH01 
on day 3 decreased, but was still more than one order of magnitude (Fig. 4A). In the second 
experiment, 2 x 107 CFU bacterial cells of 11168 or JH01 were inoculated into each flask 
containing 20 ml of MH broth with 4 µg/ml of CIPRO, yielding an initial cell density of 106 
CFU/ml. At the beginning of the treatment, no FQR mutants were detected from either 11168 
or JH01 (Fig. 4B). On day 1 after the initiation of the treatment, FQR Campylobacter 
emerged from some of the cultures of 11168 and continued to expand in numbers on day 2 
and day 3. In contrary to 11168, no FQR mutants emerged from any of the JH01 cultures 
during the three-day incubation (Fig. 4B). In the third experiment, the inoculum was 
decreased to 2 x 104 CFU per flask (initial cell density = 103 CFU/ml), and no FQR mutants 
were detected from either 11168 or JH01 after three day’s incubation (data not shown). 
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These results indicated that emergence of FQR mutants under treatment with CIPRO was 
influenced by the initial bacterial cell density and facilitated by the function of Mfd. 
 
Mfd affects the emergence of FQR mutants in vivo 
 
To determine if Mfd influences the emergence of FQR Campylobacter during in vivo 
therapeutic treatment, broiler chickens were infected with 11168 or JH01 and then treated 
with enrofloxacin administered in drinking water (50 ppm). The birds in both groups were 
quickly colonized by C. jejuni after inoculation (Fig. 5). Before the treatment with 
enrofloxacin, all birds were colonized by Campylobacter and the colonization levels (CFU/g 
feces) were similar in both groups (p > 0.05). One day after initiation of the treatment, the 
number of colonized chickens and the levels of colonization decreased drastically in both 
groups, with Campylobacter detectable only in three chickens that were inoculated with the 
wild-type strain (Fig. 5A). After that, the numbers of Campylobacter in both groups 
rebounded. On day 3 after the initiation of the treatment, all of the birds in the 11168 group 
were re-colonized by Campylobacter and remained colonized until the end of the experiment. 
For the group inoculated with JH01, 6 of the11 birds became positive with Campylobacter on 
day 3 after initiation of the treatment (Fig. 5A) and 3 birds remained negative until the end of 
the experiment. On days 3, 5 and 7 after initiation of the treatment, the average colonization 
level of the JH01-inoculated group was approximately 3 log units lower than that of the 
11168-inoculated group (Fig. 5A) and the differences were statistically significant (p < 0.05). 
The number of FQR Campylobacter in each chicken was also monitored. Prior to the 
treatment, no FQR C. jejuni was detected in any of the chickens (Fig. 5B). On day 1 after 
initiation of the treatment, the three Campylobacter-positive birds of the 11168-inoculated 
group still carried FQ-susceptible Campylobacter. However, FQR C. jejuni appeared on day 3 
in all birds of the 11168-inoculated group and in some birds of the JH01-inoculated group 
(Fig. 5B). Comparison of the total Campylobacter counts (Fig. 5A) with the numbers of FQR 
Campylobacter (Fig. 5B) revealed that the birds were re-colonized by FQR mutants after 
initiation of the treatment. The average numbers of FQR Campylobacter in the JH01-
inoculated group were approximately 3 log units lower that those of the 11168-inoculated 
group (Fig. 5B) and the differences were statistically significant (p < 0.05). These results 
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indicate that loss of Mfd significantly reduced the rates of emergence of FQR Campylobacter 
in enrofloxacin-treated chickens. 
 
Representative Campylobacter isolates obtained at different sampling times from both 
groups were tested for CIPRO MICs using E-test strips. The result showed that before 
treatment all the tested isolates from both groups were susceptible to CIPRO (MICs = 0.094 - 
0.125 µg/ml). The majority of the tested isolates from day 1 after initiation of the treatment 
were still susceptible to CIPRO (MICs = 0.094 - 0.5 µg/ml). On day 3 after the initiation of 
treatment, 21 of the 22 tested isolates (from both groups) had a CIPRO MIC of > 32 µg/ml 
and the other one had an MIC of 8 µg/ml. Similarly, the majority (44 out of 49) of the tested 
isolates from days 5 and 7 had a CIPRO MIC of >32 µg/ml and the rest had MICs from 1-24 
µg/ml. The MIC results further confirmed the differential plating results that the chickens 
were re-colonized by FQR Campylobacter.   
 
5. Discussion 
 
When Campylobacter cells were treated with a subinhibitory concentration (0.06 
µg/ml, 0.5 x the MIC) of CIPRO for 1.5 hours, no significant changes in gene expression 
were detected using the cut-off criteria defined in this study. This result was somewhat 
similar to the study with Haemophilius influenzae [61] in that the treatment with a low 
concentration of CIPRO induced few changes in gene expression, but was different from that 
study because several genes involved in SOS response were upregulated in Haemophilius 
influenzae. Prolonged treatment of Campylobacter with the subinhibitory concentration of 
CIPRO may reveal noticeable changes in gene expression, but culturing Campylobacter with 
0.06 µg/ml of CIPRO reduces its growth rate (Fig. 3), which will make the comparison with 
the non-treated control unfeasible and complicate the interpretation of the microarray results. 
To mimic clinical treatment, C. jejuni cells were exposed to a suprainhibitory dose 
(1.25µg/ml, 10 x the MIC) of CIPRO. This dose is within the concentration range of CIPRO 
in gut contents during FQ treatment in chickens [62]. The reason that we treated the samples 
for 0.5 hour instead of a longer time was to detect the primary response triggered by CIPRO, 
instead of the secondary response caused by cell death. When Campylobacter cells were 
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treated with this suprainhibitory dose for 0.5 hour, the expression of multiple genes was 
significantly altered (Table 1). Notably, the majority of the affected genes were 
downregulated and many of them are involved in cellular processes and energy metabolism 
(Table 1). This result is similar to the findings obtained with other bacteria [43, 44, 61] and 
supports the notion that reducing cellular metabolism is a common strategy utilized by 
bacteria to cope with antibiotic treatment.  
 
Within bacterial cells CIPRO interacts with gyrase and DNA, blocking DNA 
replication and transcription [18]. When exposed to CIPRO, the expression of gyrA and gyrB 
in various bacteria was either altered or unchanged [43, 61, 63]. In this study, we found that 
the expression of gyrA, gyrB, and topA was not significantly affected in Campylobacter by 
CIPRO. In addition, the expression of the genes encoding enzymes involved in DNA repair, 
recombination, or mutagenesis, such as recA, ruvABC, uvrABC, and mutS, did not change 
significantly. Only two genes involved in DNA metabolism (mfd and dnaE) were affected by 
CIPRO under the conditions used in this study (Table 1). These observations indicate that C. 
jejuni does not mount a typical SOS response under the treatment with FQ. These findings 
are also consistent with the fact that C. jejuni lacks LexA, the key regulator of bacterial SOS 
responses [46].  
 
In addition to transcription-coupled DNA repair, Mfd has been associated with other 
functions in bacteria [64]. For example, Mfd of Bacillus subtilis is involved in homologous 
DNA recombination and stationary-phase mutagenesis [65, 66]. Inactivation of the mfd gene 
of B. subtilis resulted in a great reduction in the number of prototrophic revertants to Met+, 
His+, and Leu+ during starvation [66], indicating that Mfd promotes adaptive mutagenesis. 
This finding is in contrast to the known function of Mfd in mediating mutation frequency 
decline and could be explained by the role of Mfd in promoting transcriptional bypass and 
consequently increasing the adaptive mutagenesis rates [66]. 
 
In this study we found that Mfd increases the frequency of emergence of spontaneous 
FQR mutants in Campylobacter (Fig. 2). Furthermore, the mfd mutation also decreased the 
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frequency of emergence of spontaneous streptomycin-resistant mutants in Campylobacter 
(data not shown). Together, the results convincingly showed that Mfd is an important player 
in modulating the mutation rates in Campylobacter. To our knowledge, this is the first report 
documenting the key role of Mfd in promoting spontaneous mutation rates in a bacterial 
organism. How Mfd contributes to the increased mutation rates in Campylobacter is 
unknown, but it can be speculated that transcriptional bypass mediated by Mfd may actively 
occur in replicating non-stressed Campylobacter populations, resulting in an elevated level of 
retromutagenesis (fixed changes in DNA sequence due to transcriptional mutation [67]) that 
contributes to the size of the mutant pools. This possibility remains to be examined in future 
studies. Although mfd contributes significantly to the mutation rate (Fig. 2), its expression 
level was not precisely proportional to the mutation frequencies. For example, expression of 
mfd was upregulated 3.8-fold in JH03, but its mutation frequency increased 10-fold. This 
difference is probably due to the fact that emergence of spontaneous mutants is a multi-step 
process and Mfd only contributes to one of the steps in the process. It is also possible that 
Mfd interacts with other proteins in modulating the mutation frequency. Thus, the changes in 
mfd expression level and the mutation frequency are not exactly at the same scale.  
 
Another interesting observation of this study is the upregulation of mfd by CIPRO. 
The enhanced expression may be needed for transcription repair because CIPRO treatment 
causes DNA damage, which stalls RNA polymerase. Alternatively, the increased production 
of Mfd may enhance transcriptional bypass of the non-repaired DNA lesions in order to 
maintain cell viability and/or promote mutations for resistance. This possibility is high given 
the facts that massive DNA damage incurred by a suprainhibitory dose of CIPRO may 
overwhelm the DNA repair system and Campylobacter must maintain certain levels of 
transcription to survive the treatment, that Mfd contributes significantly to the mutation rates 
to FQ resistance (Fig. 2), and that Campylobacter does not have the error-prone DNA 
polymerases, such as Pol II, Pol IV, and Pol V [48]. E. coli and other bacteria have these 
error-prone DNA polymerases [68, 69], which are repressed by LexA, but upregulated by the 
SOS response triggered by DNA damage. Once produced, the enzymes perform translesion 
DNA synthesis, allowing replication to continue without DNA repair. This special functional 
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feature results in reduced genetic fidelity, but allows for bacterial survival under stress. The 
outcome of the enhanced expression of the error-prone enzymes is the increased mutation 
rates, which contribute to the emergence of drug resistance [70]. In the absence of a SOS 
response and the error-prone DNA polymerases, Campylobacter may use Mfd as an 
alternative pathway to increase mutation rates. Thus, enhanced expression of mfd may 
represent an adaptive response of Campylobacter to the stresses imposed by CIPRO 
treatment. How CIPRO upregulates Campylobacter Mfd is unknown and further work in this 
direction is warranted.   
 
FQR Campylobacter readily emerges from a FQ-susceptible population when treated 
with FQ antimicrobials (Figs. 4 and 5). As shown in the in vitro experiment, the development 
of FQR population under CIPRO treatment is influenced by the initial cell density (Fig. 4 and 
the corresponding text) as well as the functional state of Mfd. Considering the differences in 
spontaneous mutation rate between 11168 and JH01 (Fig. 2), it was likely that the 11168 and 
JH01 inocula had different numbers of pre-existing FQR mutants, which were selected by 
CIPRO and contributed to the differences in the FQR population detected in the cultures of 
the two strains. The inoculum-dependent emergence of FQR mutants in both 11168 and JH01 
suggests that development of FQR Campylobacter under FQ treatment involves selection of 
preexisting mutants. However, the magnitude and dynamics of FQR development can not be 
totally explained by selection. For example, in some cultures FQR mutants were not 
detectible until the 2nd day of the incubation (Fig. 4). A single mutant at time zero in a culture 
flask would grow to a population of more than 2,000 cells in one day (the generation time of 
C. jejuni in MH broth is about 2 hours), which would be readily detected by the plating 
method on day 1. Thus, if selection was the only factor in the development of FQR 
Campylobacter, the latest time for detecting the pre-existing mutants in the mutant-positive 
flasks would be day 1 after initiation of the treatment. Obviously, this was not the case for all 
of the cultures because some of them did not show FQR mutants until day 2 (Fig. 4). In 
addition, some cultures were negative with FQR mutants at time zero, but showed a large 
number of mutants at day 1, which could not be easily explained by sole selection of a few 
preexisting mutants from the inocula. Considering these unexplainable observations and the 
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fact that a small fraction of the FQ-susceptible inoculum survived the killing effect as long as 
one day after the initiation of the treatment (data not shown), it was possible that new FQR 
mutants were developed during the treatment. If this occurs, Mfd may enhance the 
emergence of new mutants by promoting transcriptional bypass or other mechanisms, which 
may partly explain the differences between 11168 and JH01 in the dynamics of emergence of 
FQR mutants. Thus, there is a possibility that both selection of pre-existing mutants and de 
nova formation of mutants are involved in the development of FQR Campylobacter during 
treatment with FQ antimicrobials.  
 
The role of Mfd in the development of FQR mutants was further shown by the in vivo 
experiment, in which Campylobacter-infected chickens were treated with enrofloxacin (Fig. 
5). Previous studies have shown that therapeutic use of FQ antimicrobials in chickens 
promotes the emergence of FQR Campylobacter [19, 27, 28, 29, 30], which can be potentially 
transmitted to humans via the food chain. In this study, we showed that inactivation of mfd 
significantly reduced the development of FQR Campylobacter in chickens (Fig. 5). In fact, 
several birds in the JH01-inoculated group became negative with Campylobacter once the 
treatment was initiated. Since the mfd mutant did not show a growth defect in vitro (Fig. 3) 
and colonized chickens as efficiently as the wild-type strain (see the colonization level before 
treatment in Fig. 5), the observed differences in the development of FQR mutants were not 
due to changes in growth characteristics. These in vivo results (Fig. 5) plus the in vitro 
findings (Fig. 4) clearly showed that Mfd plays an important role in the development of FQR 
Campylobacter mutants under the selection pressure. To our knowledge, this is the first 
report that documents the role of Mfd in the development of FQ resistance in a bacterial 
pathogen. Since Mfd is highly conserved in bacterial organisms [64], it would be interesting 
to know if this finding applies to other bacterial pathogens. In addition, inhibition of Mfd 
functions may represent a feasible approach to reducing the emergence of FQR 
Campylobacter. 
 
6. Materials and Methods 
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Bacterial strains and growth conditions  
 
C. jejuni strain NCTC 11168 (ATCC 700819) was used in this study. The strain was 
routinely grown in Mueller-Hinton (MH) broth (Difco) or on MH agar at 42 °C under 
microaerobic conditions (5% O2, 10% CO2, and 85% N2). The media were supplemented 
with kanamycin (50 µg/ml) or chloramphenicol (4 µg/ml) as needed. Escherichia coli cells 
were grown at 37 °C with shaking at 200 r.p.m. in Luria Bertani (LB) medium which was 
supplemented with ampicillin (100 µg/ml) or kanamycin (30 µg/ml) when needed. 
 
DNA microarray and qRT-PCR  
 
DNA microarray was used to identify genes that were differentially expressed in C. 
jejuni 11168 treated with CIPRO. For RNA isolation, Campylobacter cells were grown for 
24 hours to the mid exponential phase (OD600 ≈ 0.1 ~ 0.15) and split into two equal portions, 
one of which was treated with CIPRO and the other served as a non-treated control. A 
subinhibitory concentration (0.06 µg/ml, 0.5 x the MIC) and a suprainhibitory dose (1.25 
µg/ml, 10 x the MIC) of CIPRO were used in the treatments. For the treatment with 0.06 
µg/ml of CIPRO, the treated and non-treated samples were incubated at 42 °C for 1.5 hours 
under microaerobic conditions, while for the treatment with 1.25 µg/ml of CIPRO, the 
samples were incubated at 42 °C for 30 min under microaerobic conditions. Immediately 
after the incubation, RNAprotectTM Bacteria Reagent (Qiagen, Valencia, CA) was added to 
the cultures to stabilize mRNA. The total RNA from each sample was extracted using the 
RNeasy Mini Kit (Qiagen). The purified RNA samples were treated with On-Column DNase 
Digestion Kit (Qiagen) followed by further treatments with DNase to remove residual DNA 
contamination. RNA samples were extracted from 6 independent treatments with each 
concentration of CIPRO. Absence of contaminating DNA in the RNA samples was 
confirmed by RT-PCR. The concentration of total RNA was estimated with the NanoDrop 
ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA), and the integrity and size 
distribution of the purified RNA was determined by denaturing agarose gel electrophoresis 
and ethidium bromide staining. The quality of total RNA was further analyzed using the 
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Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), which showed the 
good quality and integrity of the RNA samples (Data not shown). 
 
cDNA synthesis and labeling, microarray slide (Ocimum Biosolutions) hybridization, 
Data collection and normalization, and statistical analysis were performed as described in a 
previous publication [71]. For each type of treatment (0.06 µg/ml for 1.5 hours or 1.25 µg/ml 
for 30min), six microarray slides were hybridized with RNA samples prepared from 6 
independent experiments. For this study, we chose p-value < 0.05 and the change ≥ 1.5-fold 
as the cutoff for significant differential expression between the treated and non-treated 
samples. Representative genes identified by the DNA microarray were further confirmed by 
qRT-PCR as described in a previous work [72]. The primers used for qRT-PCR are listed in 
Table 2. 
 
Insertional mutation of mfd  
 
An isogenic mfd (cj1085c) mutant of strain NCTC 11168 was constructed by 
insertional mutagenesis. Primers mfd-F2 (5’-TGTTGATGGAGAGTTAAGTGGTAT-3’) 
and mfd-R2 (5’-AATAGCATTCATAGCGACTTCTGTT -3’) were designed from the 
published genomic sequence of this strain [48] and used to amplify a 1.8-kb fragment 
spanning the 5’ region of mfd.  Amplification was performed with Pfu Turbo® DNA 
Polymerase (Stratagene, La Jolla, CA, USA). The blunt-ended PCR product was purified 
using a QIAquick PCR purification kit (Qiagen, Valencia, CA, USA), ligated to SmaI–
digested suicide vector pUC19, resulting in the construction of pUC-mfd, which was then 
transformed into E. coli DH5α. Since a unique EcoRV site (which generates blunt ends) 
occurs in the cloned mfd fragment, pUC-mfd was digested with EcoRV to interrupt the mfd 
gene. Primers KanNco-F (5’ CTT ATC AAT ATA TCC ATG GAA TGG GCA AAG CAT 
3’) and KanNco-R (5’ GAT AGA ACC ATG GAT AAT GCT AAG ACA ATC ACT AAA 
3’) were used to amplify the aphA3 gene (encoding kanamycin resistance) from the pMW10 
vector [73] by using Pfu Turbo® DNA polymerase (Stratagene). The aphA3 PCR product 
was directly ligated to EcoRV-digested pUC-mfd to obtain construct pUC-mfd-aphA3, in 
which the aphA3 gene was inserted within mfd (the same direction as the transcription of mfd) 
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and the insertion was confirmed by PCR using primers mfd-F2 and Kana-intra (5’ GAA 
GAA CAG TAT GTC GAG CTA TTT TTT GAC TTA 3’). The pUC-mfd-aphA3 construct, 
which served as a suicide vector, was electroporated into C. jejuni NCTC 11168. 
Transformants were selected on MH agar containing 10 µg/ml of kanamycin. Inactivation of 
the mfd gene in the transformants by insertion of the ahpA3 gene was confirmed by PCR 
using primers mfd-F2 and mfd-R2 (Fig. 1B). The mfd mutant of NCTC 11168 was named 
JH01. 
 
Complementation of the mfd mutant in trans  
 
The entire mfd gene including its putative ribosome binding site was amplified from 
strain 11168 by PCR using primers mfd-F5 (5’-
CGCTTCCGCGGAACTAGTAAAATTAAAGAAGATACTATC-3’) and mfd-R3 (5’-
GGCTTTAAATAATCTTTTCGAGCTCTATAAATT-3’). The underlined sequences in the 
primers indicate the restriction sites for SacI and SacII, respectively. The PCR product was 
digested with SacI and SacII, and was then cloned into the plasmid construct pRY112-pABC 
to generate pRY112-mfd, in which the mfd gene was fused to the promoter of cmeABC. 
pRY112-pABC was made by cloning the promoter sequence of cmeABC [74] to shuttle 
plasmid pRY112 [75]. The promoter DNA of cmeABC was amplified by primers BSF (5’ 
AAAAGGATCCTAAATGGAATCAATAG 3’) and AR2 (5’ 
TGATCTAGATCATACCGAGA 3’), digested with BamHI and XbaI, and cloned into 
pRY112. There were two reasons that we used the promoter of cmeABC in the expression of 
mfd. First, the 5’ end of mfd overlaps with its upstream gene and the native promoter for mfd 
was unknown. Second, the promoter of cmeABC is moderately active in Campylobacter [74], 
preventing over- or under-expression of mfd. The constructed plasmid pRY112-mfd was 
sequenced and confirmed that no mutations in the cloned sequence occurred. For 
complementation, the shuttle plasmid pRY112-mfd was transferred into JH01 by conjugation. 
The complemented strain was named JH02. Limited passage of JH02 in MH broth without 
antibiotics indicated that the complementing plasmid was stable in the construct (data not 
shown). The shuttle plasmid carrying the mfd gene was also transferred to wild-type 11168 to 
generate strain JH03 for overexpression of the mfd gene. 
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Growth rates in MH broth with or without CIPRO  
 
To compare the growth kinetics of the mfd mutant with that of the wild-type, a fresh 
culture of each strain was inoculated into MH broth (initial cell density of OD600 = 0.05) 
and the cultures were incubated at 42 °C under microaerobic conditions. To determine if the 
mutation affects C. jejuni growth with a subinhibitory concentration of CIPRO, the various 
strains were grown in MH broth with 0.06 µg/ml of CIPRO (0.5 x the MIC). Culture samples 
were collected and measured for OD600 at 0, 3, 6, 12, 24 and 48 hours post-inoculation. 
 
Antibiotic susceptibility test  
 
The minimum inhibitory concentration (MIC) of CIPRO was determined by using E-
test strips (AB Biodisk, Solna, Sweden) as described in the manufacturer's instructions. The 
detection limit of the E-test for CIPRO was 32 µg/ml. The MICs of erythromycin, ampicillin 
and streptomycin for C. jejuni NCTC 11168, JH01, JH02, and JH03 were determined using a 
standard microtiter broth dilution method described previously [24]. Each MIC test was 
repeated at least three times to confirm the reproducibility of the MIC patterns. The 
antibiotics used in this study were purchased from Sigma Chemical Co. (erythromycin, 
ampicillin, streptomycin) or ICN Biomedicals Inc. (CIPRO). 
 
Frequencies of emergence of spontaneous FQR mutants in vitro  
 
Wild-type 11168, JH01, JH02 and JH03 were compared for the spontaneous mutation 
rates to CIPRO resistance. In each experiment, each of the 4 strains was inoculated into three 
flasks, each of which contained 30 ml of antibiotic-free MH broth. The cultures were 
incubated to the mid logarithmic phase (OD600 ≈ 0.15) under microaerobic conditions. The 
culture in each flask was collected by centrifugation and resuspended in 1 ml of MH broth. 
The total CFU in each culture was measured by serial dilutions and plating on MH agar 
plates, while the number of FQR mutants was detected using MH agar plates containing 1, 2 
or 4 µg/ml CIPRO. The frequency of emergence of FQR mutants was calculated as the ratio 
of the CFU on CIPRO-containing MH agar plates to the CFU on antibiotic-free MH agar 
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plates after 2 days of incubation at 42°C under microaerobic conditions. This experiment was 
repeated five times. The mutation frequency data were log-transformed for statistical analysis. 
One-Way ANOVA followed by Tukey test was used to determine the significance of 
differences in the levels of spontaneous mutation rates among the strains. The data were also 
analyzed by the Wilcoxon rank-sum test to allow for non-normality. For the comparisons 
discussed in Results, the conclusion of the two tests was the same at significance level 0.05. 
 
Sequence analysis of the QRDR of gyrA  
 
Representative FQR colonies were selected for determination of the point mutations in 
gyrA. The QRDR of gyrA was amplified by PCR using primer pair GyrAF1 (5'-
CAACTGGTTCTAGCCTTTTG-3') and GyrAR1 (5'-AATTTCACTCATAGCCTCACG-3') 
[76]. The amplified PCR products were purified with the QIAquick PCR purification kit 
(Qiagen) prior to sequence determination. DNA sequence analysis was carried out using an 
automated ABI Prism 377 sequencer (Applied Biosystems, Foster City, CA, USA) and 
analyzed by the Omiga 2.0 (Oxford Molecular Group) sequencing analysis software. 
 
In vitro treatment with CIPRO 
 
To determine if Mfd affects the development of FQR mutants under treatment with 
CIPRO, wild-type 11168 and JH01 were treated in MH broth with 4 µg/ml (32 x the MIC) of 
CIPRO. Wild-type 11168 and JH01 were grown on antibiotic-free MH agar plates under 
microaerobic conditions. After 20 hours of incubation, the cells were collected and 
resuspended in MH broth for inoculation. Three treatment experiments were conducted using 
three different initial cell densities. In experiment 1, each strain was inoculated into 3 100-ml 
flasks with MH broth containing 4 µg/ml of CIPRO and the initial cell density was 107 
CFU/ml. The cultures were incubated microaerobically at 42 oC. Aliquots of the cultures 
were collected at different time points (0, 1, 2, 3 days post-inoculation) and plated onto 
regular MH plates for enumeration of the total bacterial number and onto MH plates 
containing 4 µg/ml of CIPRO for counting FQR colonies. In experiments 2 and 3, the cultures 
were treated in the same way, but the initial cell densities were 106 and 103 CFU/ml, 
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respectively. Experiment 1 was repeated three times, while experiments 2 and 3 were each 
repeated twice. 
 
The transcription level of Cj1084c 
 
To determine if the insertional mutation in mfd affected the expression of the 
downstream gene Cj1084c (encoding a possible ATP/GTP-binding protein), RT-PCR was 
performed to assess the expression of Cj1084c. Total RNA was isolated from C. jejuni 11168 
and JH01 using the RNeasy Kit (Qiagen). The purified RNA samples were treated with On-
Column DNase Digestion Kit (Qiagen) followed by further treatments with DNase to remove 
DNA contamination. The Cj1084c-specific primers Cj1084cF (5' TTG CCT TAG CAG ATA 
TCA T 3') and Cj1084cR (5' ACC ACT TCT ACT TGC TCT TA 3') were used to amplify a 
430 bp region of the gene in a conventional one-step RT-PCR by using the SuperScript™ III 
One-Step RT-PCR kit (Invitrogen®). An RT-PCR mixture lacking the RT was included as a 
negative control. 
 
Emergence of FQR mutants in enrofloxacin-treated chickens  
 
To examine if Mfd plays a role in the emergence of FQR Campylobacter during in 
vivo FQ treatment, a chicken experiment was performed using 11168 and JH01. Day-old 
broiler chickens (Ross X Cobb) were obtained from a commercial hatchery and randomly 
assigned to 2 groups (11 birds per group). Each group of chickens was maintained in a 
sanitized wire-floored cage. Feed and water were provided ad libitum. Prior to inoculation 
with Campylobacter, the birds were tested negative for Campylobacter by culturing cloacal 
swabs. At day 3 of age, the two groups of chickens were inoculated with 11168 and JH01, 
respectively, at a dose of 106 CFU/chick via oral gavage. Six days after the inoculation, the 
birds were treated with 50 ppm enrofloxacin. The treatment was administered in drinking 
water and lasted for five consecutive days. During the treatment, only medicated water was 
given to the birds to ensure enough consumption. Cloacal swabs were collected periodically 
before and after enrofloxacin treatment until the end of the experiment. Each swab was 
serially diluted in MH broth and plated onto two different types of MH plates: one containing 
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Campylobacter-specific growth supplements (SR 084E and SR117 E; Oxoid Ltd., 
Basingstoke, England) for the enumeration of total Campylobacter cells and the other 
containing 4 µg/ml of CIPRO in addition to the same selective agents and supplements to 
recover FQR Campylobacter in each chicken. At each sampling time, at least one 
Campylobacter colony from each chicken were selected from the regular MH agar plates (no 
CIPRO) for the determination of CIPRO MICs using the E-test (AB Biodisk). The 
colonization data (CFU/g feces) were log-transformed and used for statistical analysis. The 
significance of differences in the level of colonization between the two groups was 
determined using Student’s t-test, Welch’s t-test to allow for non-constant variation across 
treatment groups, and the Wilcoxon rank-sum test to allow for non-normality. The 
conclusion of all three tests was the same at significance level 0.05. 
 
Microarray data accession number  
 
The microarray data have been deposited in the NCBI Gene Expression Omnibus 
(GEO; http://www.ncbi.nlm.nih.gov/geo/) database and the accession number is GSE10471. 
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TABLE 1. Genes differentially expressed in the presence of ciprofloxacin 
Table 1 Genes differentially expressed in the presence of ciprofloxacin 
n-Fold change 
Gene ID and Functional Category 
P-Value Q-Value 
Microarray qRT-PCR 
Cell membrane     
Cj0205 uppP, undecaprenyl-diphosphatase 0.0135 0.130143 1.59 6.1 
Cj0735 putative periplasmic protein 0.0186 0.14811 1.70 NT* 
Cj0824 uppS, undecaprenyl diphosphate synthase 0.0099 0.120356 1.52 2.1 
Cj1351 pldA, phospholipase A 0.0046 0.094812 2.02 2 
Cj0033 putative integral membrane protein 0.0033 0.086471 -1.52 NT 
Cj0179 exbB1, biopolymer transport protein 0.0412 0.217646 -1.88 NT 
Cj0486 putative sugar transporter 0.0043 0.091967 -1.57 NT 
Cj0553 putative integral membrane protein 0.0106 0.121714 -1.59 NT 
Cj0834c ankyrin repeat-containing possible periplasmic protein 0.0089 0.110719 -1.51 NT 
Cj1013c putative cytochrome C biogenesis protein 0.0058 0.096095 -1.52 NT 
Cj1662 putative integral membrane protein 0.0055 0.096095 -1.68 NT 
Cj1663 
 
putative ABC transport system ATP-binding protein 0.0002 0.067622 -1.75 NT 
      
DNA replication, recombination and repair 
Cj1085c mfd, transcription-repair coupling factor 0.0029 0.082832 1.57 2.2 
Cj0718 dnaE, DNA polymerase III, alpha chain 4.07E-05 0.052459 -1.62 -1.98 
      
Cellular process and energy metabolism 
Cj0041 putative flagellar hook-length control protein 0.0357 0.204764 1.93 NT 
Cj0065c folk, putative 2-amino-4-hydroxy-6- 
hydroxymethyldihydropteridine pyrophosphokinase 
0.0117 0.129371 1.54 NT 
Cj1030c lepA, GTP-binding protein homolog 0.0057 0.210454 1.54 NT 
Cj1280c putative ribosomal pseudouridine synthase 0.0252 0.170564 1.50 NT 
Cj0009 gltd, glutamate synthase (NADPH) small subunit 0.0007 0.067622 -1.74 NT 
Cj0123c putative tRNA-dihydrouridine synthase 0.0020 0.076881 -1.87 -2.1 
Cj0227 argD, acetylornithine aminotransferase 0.0208 0.151677 -1.69 NT 
Cj0283c cheW, chemotaxis protein 0.0125 0.130143 -1.52 NT 
Cj0415 putative GMC oxidoreductase subunit 0.0191 0.148174 -1.53 NT 
Cj0490- ald, putative aldehyde dehydrogenase C-terminus 0.0013 0.076653 -1.80 NT 
Cj0537 oorb, OORB subunit of 2-oxoglutarate:acceptor 
oxidoreductase 
0.0024 0.076881 -1.67 -2.23 
Cj0734c hisJ, histidine-binding protein precursor 0.0404 0.214389 -1.59 NT 
Cj0764c speA, biosynthetic arginine decarboxylase 0.0116 0.129371 -1.97 -1.96 
Cj0767c kdtB,3-deoxy-D-manno-octulosonic-acid transferase 0.0370 0.207688 -1.58 NT 
Cj1264c hydD, putative hydrogenase maturation protease 0.0009 0.067622 -2.13 - 6.7 
Cj1265c hydC, Ni/Fe-hydrogenase B-type cytochrome subunit 0.0016 0.076881 -2.12 NT 
Cj1266c hydB, Ni/Fe-hydrogenase large subunit 0.0032 0.086244 -1.56 NT 
Cj1364c fumC, fumarate hydratase 0.0255 0.171473 -1.52 NT 
Cj1476c pyruvate-flavodoxin oxidoreductase 0.0133 0.130143 -1.55 NT 
Cj1566c nuoN, NADH dehydrogenase I chain N 0.0039 0.088549 -2.03 -2.71 
Cj1567c 
Cj1624c 
Cj1682c 
Cj1688c 
Cj1717c 
nuoM, NADH dehydrogenase I chain M 
sdaA, L-serine dehydratase 
gltA, citrate synthase 
secY, preprotein translocase subunit 
leuC, 3-isopropylmalate dehydratase large subunit 
0.0055 
0.0046 
0.0167 
0.0021 
0.0018 
0.096095 
0.094812 
0.142007 
0.076881 
0.076881 
-1.60 
-1.58 
-1.54 
-1.63 
-1.61 
NT 
NT 
NT 
-2.15 
NT   
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TABLE 1—Continued 
 
n-Fold change Gene ID and Functional Category P-Value Q-Value 
Microarray qRT-PCR 
Unknown function 
Cj0163c hypothetical protein 0.0204 0.151393 1.60 NT 
Cj0814 hypothetical protein 0.0002 0.067622 1.99 NT 
Cj0959c hypothetical protein 0.0233 0.160562 1.50 NT 
Cj1025c hypothetical protein 0.0389 0.210454 1.54 NT 
Cj0125c hypothetical protein Cj0125c 0.0031 0.084482 -1.53 NT 
Cj0554 hypothetical protein 0.0083 0.107589 -1.71 NT 
 
* NT:  Not tested 
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TABLE 2. Oligonucleotide primers used in qRT-PCR 
Table 2 Oligonucleotide primers used in qRT-PCR 
Primer Sequence Gene amplified 
16s RNA F 5’-TAC CTG GGC TTG ATA TCC TA-3’ 
16s RNA R 5’-GGA CTT AAC CCA ACA TCT CA-3’ 
16s RNA 
 
Cj0123cF 5’ CGC CTT GAT CTT TGT AGT GTT TT 3’ 
Cj0123cR 5’ TGA AAT CAA AAG CGG TAA AAG TG 3’ 
cj0123c 
Cj0824F1 5’-CAA AGT GCG TCA CAA TGC TT-3’ 
Cj0824R1 5’-GAT TTA TCG CGC TTG GAA GA-3’ 
cj0824 (uppS) 
Cj1351F1 5’-ATC CCC TTG GCA TTA GCT CT-3’ 
Cj1351R1 5’-TGG AAT TTC GCC TCA CTA TT-3’ 
cj1351 (pldA) 
Cj1264cF1 5’-GCT TAG GCG TTC ATC TTT GC-3’ 
Cj1264cR1 5’-CAA AGC CAA AGT TCC ACC AT-3’ 
cj1264c 
Cj1085cF1 5’-TGT TTT GCA AAC TCC ACC AG-3 
Cj1085cR1 5’-ATT TTG CCC ACC ACG TCT TA-3’ 
cj1085c (mfd) 
Cj0205F1 5’-GAA AAG TTG CGG CTG AGT TT-3 
Cj0205R1 5’-AAT TTG CAT TGC CAA GAA GC-3’ 
cj0205 (uppP) 
Cj0537F1 5’-GGC AAT TGG TGG AAA TCA TAC TA-3’ 
Cj0537R1 5’-TGG AGT AGT TGG AGA AGT TTG AGA-3’ 
cj0537 
Cj0718F 5’-GGA CTT GGG GCT ATA AAA AGT GT 3’ 
Cj0718R 5’-CGG TTT ATT TTG GTG GGA TCT AT-3’ 
cj0718(dnaE) 
Cj1688cF1 5’-GCC TGA ATT GAT TTG TCC TAC AG-3’ 
Cj1688cR1 5’-CGA ACA AAT CAC ACA AAG AGG TA-3’ 
cj1688c (secY) 
Cj0764cF1 5’-TTC AGC TGC AAT AAA GCC TAT GT-3’ 
Cj0764cR1 5’-ATA ATA ACG AAG GCG CAC CTA TT-3’ 
cj0764c (speA) 
Cj1566cF1 5’-CAT AAA TTT ACC CCA AAA CAC TCC-3’ 
Cj1566cR1 5’-GAG AGT TTA AAT GGG CTT TTG GT-3’ 
cj1566c 
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Fig. 1 Insertional mutation of mfd and its impact on the transcription of cj1084c 
Fig. 1. Insertional mutation of mfd and its impact on the transcription of cj1084c. (A) 
Diagram depicting the genomic organization of mfd and its flanking regions. ORFs and their 
directions of transcription are indicated by boxed arrows. The location of the inserted 
kanamycin resistance gene (aphA3) in mfd is indicated. (B) PCR confirmation of the aphA3 
insertion into the mfd gene in JH01. Lane 1 shows the PCR product from 11168, while Lane 
2 shows the PCR product of JH01. The primers used in the PCR were mfd-F2 and mfd-R2. 
Lane M contains 1 kb DNA size markers (Promega). (C) RT-PCR analysis of cj1084c 
expression in strains 11168 and JH01. The same amount of total RNA from 11168 (Lane 1) 
and JH01 (Lane 2 and 3) were used as template in the RT-PCR. Lanes 1 and 2 are normal 
RT-PCR reactions. Lane 3 is a RT-PCR reaction without reverse transcriptase (DNA-free 
control for the RNA preparation). In Lane 4, genomic DNA of 11168 was used as template 
(positive control for PCR). 
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Fig. 2 Frequencies of emergence of spontaneous FQR mutants in different C. jejuni strains 
Fig. 2. Frequencies of emergence of spontaneous FQR mutants in different C. jejuni strains 
including the wild-type 11168, the mfd mutant (JH01), the complemented mfd mutant (JH02), 
and the mfd-overexpressing construct (JH03). Three different concentrations of CIPRO (1, 2, 
and 4 µg/ml, respectively) were used in the detection plates to count FQR colonies. Each bar 
represents the mean ± standard deviation of frequencies from three independent cultures. The 
bars labeled with different letters indicate that they are significantly different (P < 0.05). 
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Fig. 3 Growth kinetics of various C. jejuni constructs in culture media 
Fig. 3. Growth kinetics of various C. jejuni constructs in culture media. The strains were 
grown in MH broth (A) or MH broth supplemented with 0.06 µg/ml of CIPRO (B).  
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Fig. 4 Development of FQR mutants from 11168 and JH01 grown in MH broth supplemented 
with 4 µg/ml of CIPRO 
Fig. 4. Development of FQR mutants from 11168 (solid circle) and JH01 (triangle) grown in 
MH broth supplemented with 4 µg/ml of CIPRO. In panel A, the initial cell density (at time 0) 
of each culture was 107 CFU/ml, while in panel B the initial cell density was 106 CFU/ml. 
Each symbol represents the number of FQR mutants in a single culture. Each horizontal bar 
represents the mean log10 CFU/ml from each strain at a given time. Panel A displays the 
results of 3 independent experiments, while panel B represents the results of two 
independents experiments. The detection limit of the plating method is 1 CFU/ml. 
 
 
 
92 
 
 
Fig. 5 Development of FQR Campylobacter mutants in chickens initially infected with FQ-
susceptible Campylobacter, but treated with enrofloxacin 
Fig. 5. Development of FQR Campylobacter mutants in chickens initially infected with FQ-
susceptible Campylobacter, but treated with enrofloxacin. (A) The level of total 
Campylobacter in each chicken inoculated with the wild-type 11168 (open circle) or the mfd 
mutant strain (JH01; solid circle). The treatment with enrofloxacin started on day 0 and 
lasted for five consecutive days (indicated by a bracket on top of the panel). (B) The level of 
FQR Campylobacter in each chicken inoculated with the wild-type (open circle) or the mfd 
mutant (solid circle). In both panels, each symbol represents the number of Campylobacter in 
a single bird. Each group includes eleven chickens and the mean of each group at a given 
time is indicated by a horizontal bar. A chicken is considered negative if the level of 
colonization was below the detection limit (100 CFU/ g of feces). 
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1. Abstract  
 
Our previous work showed that acquisition of fluoroquinolone (FQ) resistance via a 
specific GyrA mutation (Thr-86-Ile) enhances the in vivo fitness of FQ-resistant mutants in 
the absence of antibiotic selection pressure. In this study, we further confirmed the role of the 
Thr-86-Ile mutation in modulating Campylobacter fitness by reverting the mutation. 
Reversion of this mutant allele to a wild-type allele resulted in the loss of the fitness 
advantage, consistent with our previous findings. To understand how the Thr-86-Ile mutation 
affects Campylobacter fitness, we initiated work to determine if this mutation alters the 
physiological function of DNA gyrase. Recombinant wild-type gyrase and mutant gyrases 
with three different types of mutations (Thr-86-Ile; Thr-86-Lys; and Asp-90-Asn) were 
generated in E. coli and compared for their supercoiling activities using an in vitro assay. The 
mutant gyrase with the Thr-86-Ile change showed a greatly reduced supercoiling activity 
compared with the wild-type gyrase and other mutant gyrases. In addition, we measured 
DNA supercoiling within Campylobacter cells using a reporter plasmid. Consistent with the 
results from the in vitro supercoiling assay, the FQ-resistant mutant Campylobacter carrying 
the Thr-86-Ile change in GyrA showed much less DNA supercoiling than the wild-type strain 
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and the mutant strains carrying other mutations. Together, these results clearly indicate that 
the Thr-86-Ile change in GyrA confers a high-level resistance to FQs and significantly 
reduces the supercoiling activity of the enzyme in Campylobacter.  
 
2. Introduction 
 
Campylobacter jejuni, a Gram-negative microaerobic bacterium, has emerged as the 
leading bacterial cause of foodborne diseases in the United States and other developed 
countries (45). The estimated number of human cases of campylobacteriosis in the U.S. is 
more than 2 million per year (30, 42). The medical and productivity costs resulting from C. 
jejuni infection are estimated at 0.6 to 1.0 billion dollars each year in the U.S. (8). Antibiotic 
treatment using fluoroquinolone (FQ) or erythromycin is recommended when the infection 
by Campylobacter is severe or occurs in immunocompromised patients (12, 35). However, 
Campylobacter is increasingly resistant to FQ antimicrobials, which has become a major 
concern for public health (12, 16, 48). Although FQ antimicrobials have been banned since 
2005 in poultry production in the U.S., FQ-resistant (FQR) Campylobacter continues to 
persist on poultry farms (25, 39, 40).  
The main targets of FQs in bacteria are DNA gyrases and/or topoisomerase IV (11, 
18). In Gram-negative bacteria, DNA gyrase, a type II topoisomerase, is the primary target of 
FQ antibiotics, while topoisomerase IV is the main target of FQs in Gram-positive bacteria 
(18). Once inside bacterial cells, FQ antimicrobials form stable a complex with the target 
enzymes and trap the enzymes on DNA, resulting in double-stranded breaks in DNA and 
bacterial death (10, 44, 49). Bacterial DNA gyrase is essential for bacterial viability. It 
catalyzes ATP-dependent negative supercoiling of DNA and is involved in DNA replication, 
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recombination, and transcription (9). The enzyme consists of two subunits (subunits A and 
B) that combine into the A2B2 complex to form a functional enzyme. The two subunits are 
encoded by the genes gyrA and gyrB, respectively. In Campylobacter, resistance to FQ 
antimicrobials is mediated by point mutation in the quinolone resistance-determining region 
(QRDR) of gyrA in conjunction with the function of the multidrug efflux pump CmeABC (3, 
12, 13, 27). No mutations in gyrB have been implicated in FQ resistance in Campylobacter 
(3, 37, 38). Acquisition of high-level FQ resistance in Campylobacter does not require 
stepwise accumulation of point mutations in gyrA. Instead, a single point mutation in gyrA 
can lead to clinically relevant levels of resistance to FQ antimicrobials (13, 27, 41). Specific 
mutations at positions Thr-86, Asp-90 and Ala-70 in GyrA have been linked to FQ resistance 
in C. jejuni (12, 27, 47). Specifically, the Thr-86-Ile change (mediated by the C257T 
mutation) is the most commonly observed mutation in FQR Campylobacter isolates and 
confers high-level (ciprofloxacin MIC 16 µg/ml) resistance to FQ, whereas the Thr-86-Lys 
and Asp-90-Asn mutations are less common and are associated with intermediate-level FQ 
resistance (15, 27, 41, 47).  
Genes targeted by antibiotics are usually essential for bacterial physiology. Thus 
resistance-conferring mutations in target genes are often associated with changes in 
physiological processes, resulting in reduced growth rate and fitness in the absence of 
antibiotic selection (1, 2, 20, 21). However, bacteria can develop compensatory mutations to 
ameliorate the fitness defect associated with antimicrobial resistance (1, 6, 7, 33, 34). In 
some situations, antibiotic-resistant mutants show little or no fitness cost even without 
compensatory mutations (43). A previous study by Luo et. al. showed FQR Campylobacter 
carrying the C257T mutation (leading to a Thr-86-Ile substitution in the GyrA subunit) was 
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able to colonize and persist in chickens as efficiently as the FQ-susceptible (FQS) strains in 
the absence of FQ. Pairwise competitions using clonally or isogenic strains further 
demonstrated that the FQR isolates outcompeted the FQS strains in the majority of the 
competing pairs in chickens (26), suggesting that acquisition of FQ resistance enhances the in 
vivo fitness of FQR Campylobacter. How the resistance-conferring mutation affects 
Campylobacter fitness is unknown. GryA plays an essential role in maintaining the 
topological configuration of DNA by introducing negative superhelical turns in DNA. Work 
performed with Escherichia coli and Pseudomonas revealed that antibiotic resistance-
conferring mutations in GyrA reduced the supercoiling activity of the enzyme in (5, 20). It is 
also known that changes in DNA supercoiling affect bacterial adaptive responses to various 
environmental signals including heat shock, cold shock, osmolar stress, and oxidative stress 
(24, 46). Based on the available evidence, we hypothesize that the resistance-conferring 
mutations in FQR Campylobacter may affect the enzymatic function of GyrA and modulate 
the DNA supercoiling status within the bacterial cells, which leads to fitness changes in FQR 
Campylobacter. 
 
To begin to examine our hypothesis, we conducted a series of experiments in this 
study to determine the impact of various point mutations on the supecoiling activities of 
GyrA. We first confirmed the specific role of Thr-86-Ile mutation of GyrA in influencing 
Campylobacter fitness in chickens by reverting the mutation to a wild-type allele. We then 
prepared recombinant gyrases with three different types of mutations [C257T (Thr-86-Ile), 
C257A (Thr-86-Lys), and G268A (Asp-90-Asn)] and compared their supercoiling activity 
with that of the wild-type gyrase in the presence or absence of ciprofloxacin using an in vitro 
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supercoiling assay. Also we determined the impact of the mutations on in vivo supercoiling 
(within Campylobacter cells) using a reporter plasmid. Our results consistently showed that 
the Thr-86-Ile change in GyrA was directly linked to the fitness change in Campylobacter 
and greatly reduced the supercoiling activitity of GyrA, while other GyrA mutations, 
although reduced the susceptibility to ciprofloxacin, did not affect the supercoiling activity of 
the gyrase. 
 
3. Materials and Methods 
 
Bacterial strains and growth conditions 
 
The FQS strains and FQR mutant strains (carrying different point mutations in gyrA) 
used in this study are listed in Table 1. The strain was routinely grown in Mueller-Hinton 
(MH) broth (Difco) or agar at 42 °C under microaerobic conditions (10% CO2, 5% O2, and 
85% N2). Campylobacter-specific growth supplements and selective agents (Oxoid) were 
added to media when needed to recover Campylobacter from chicken feces. MH media were 
supplemented with kananmycin (50 µg/ml) or chloramphenicol (4 µg/ml) as needed. 
Escherichia coli (E. coli) cells were grown at 37 °C with shaking at 200 r.p.m. in LB medium 
which was supplemented with ampicillin (100µg/ml) or kanamycin (30µg/ml). 
 
Reversion of the gyrA mutation (Thr-86-Ile) 
 
To formally define the role of the C257T mutation in influencing Campylobacter 
fitness, the specific mutation (C257T) in gyrA of isolates 62301R33 was reverted to wild-
type sequence by using a method reported by Ge et. al. (13). A chloramphenicol resistance 
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(Cmr) cassette, which was used as a selective marker, was inserted in the cj1028c gene 
immediately upstream of gyrA. Cj1028c and gyrA are tandemly positioned on the 
chromosome of C. jejuni. An 850-bp fragment containing the 3' region of Cj1028c, the 
intergenic region, and the gyrA sequence up to the mutation site was amplified by PCR using 
C. jejuni 62301R33 as a template and gyrA1028F and gyrA257WR (corresponding to the 
wild-type gyrA sequence) as primers (Table 2) and then cloned into a pGEMT-Easy 
(Promega). The construct was linearized using EcoRV, which cuts once within the cloned 
cj1028c sequence, ligated with a blunt-ended Cmr cassette, and electroporated into E. coli 
JM109. Recombinant plasmids were purified from E. coli JM109 and used to transform the 
parent strains C. jejuni 62301R33 by electroporation. Transformants were selected on MH 
agar containing chloramphenicol 10 mg/L and analyzed by PCR and DNA sequencing, 
confirming the insertion of the cat cassette into Cj1028c and the simultaneous replacement of 
the mutant gyrA with the wild-type allele. This revertant was named 62301R33S. To make an 
isogenic pair for the revertant for in vivo competition, the cat gene was also inserted into 
Cj1028c of isolate 62301R33 without changing the C257T mutation in gyrA. Primers 
gyrA1028F and gyrA257m(T) were used for this purpose (Table 2). The obtained construct 
was named 62301R33R. The ciprofloxacin MIC in the revertant 62301R33S was restored to 
the wild-type level (0.125µg/ml), while 62301R33R with the cat gene inserted into Cj1028c 
retained the ciprofloxacin MIC at 32 µg/ml. S3B R33S and 62301R33R were equally motile 
as determined by motility assay. Using the same strategy, a point mutation (C257T) in gyrA 
was introduced into FQS NCTC 11168. The generated FQR mutant strain and its isogenic FQS 
strain, both of which contained a Cmr insertion in cj1028c, were named 11168 (R) and 11168 
(S), respectively (Table 1).  
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In vivo colonization and pairwise competition 
 
Chicken experiments were performed using pairwise competition as described 
previously (26). Three groups (10-11 birds/group) of Campylobacter-free chickens were 
inoculated with about 107 CFU of 62301R33S, 62301R33R, or a mixture (approximately 1:1) 
of the two strains via oral gavage. During the entire experiment, antibiotic-free feed and 
water were given to the chickens. Thus, antibiotic selection pressure was not involved in the 
competition. After inoculation, cloacal swabs were collected from the chickens at days 3, 6, 
and 9 for culturing Campylobacter. Each fecal suspension was serially diluted in MH broth 
and plated simultaneously onto two different types of culture media: conventional 
Campylobacter selective plates for recovering the total Campylobacter colonies and the 
selective MH plates supplemented with 4 µg/ml ciprofloxacin for recovering FQR 
Campylobacter colonies. Competion index (CI) was calculated as described in reference (26). 
To confirm the results from the differential plating, 10–15 Campylobacter colonies were 
selected randomly for each group from the conventional selective plates (no ciprofloxacin) at 
each sampling time and tested for ciprofloxacin MICs using Etest strips (AB Biodisk, Solna, 
Sweden). In the second chicken experiment, the same pairwise experiment was performed 
using the isogenic pair of 11168(S) and 11168(R). 
 
In both experiments, the detection limit of the plating methods was 100 CFU/g of 
feces. The statistic analyses that were used to determined the significance of differences in 
 
 
 
100 
the level of colonization between the two groups were performed as described in a previous 
publication (17). 
 
Production and purification of GyrA and GyrB 
 
 Full-length histidine (His)-tagged recombinant gyrases including wild-type (WT) 
GyrA, three mutant GyrA, and GyrB were produced in E. coli by using the pQE-30 vector of 
the QIAexpress expression system (Qiagen). The complete coding sequences of gyrA in 
strains 62301S2 (no mutation in GyrA), 62301R33 (with the Thr-86-Ile change in GyrA), 
52901-II2 (with the Thr-86-Lys change in GyrA) and 62301R37 (with the Asp-90-Asn 
change in GyrA) were amplified using primers gyrA-F-2 and gyrA-R. The complete coding 
sequence of gyrB in strain 62301S2 was amplified using primers gyrB-F-J2 and gyrB-R-J. A 
restriction site (underlined in the primer sequences) was attached to the 5’ end of each primer 
to facilitate the directional cloning of the amplified PCR product into the pQE-30 vector. The 
amplified PCR product was digested with SphI and SalI, and then ligated into the pQE30 
vector, which was previously digested with the same enzymes. Each plasmid in the E. coli 
clone expressing a recombinant peptide was sequenced, revealing no undesired mutations in 
the coding sequence. These His-tagged recombinant GyrA and GyrB proteins were expressed 
and purified to near-homogeneity under native conditions by following the procedure 
supplied with the pQE-30 vector. Then these proteins were analyzed by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). To remove imidazole, the purified proteins were washed 
extensively with 10 mM Tris-HCl using Centricon YM-50 (Millipore).  
 
 
 
 
101 
In vitro supercoiling assay 
  
DNA supercoiling activity was assayed by monitoring the conversion of relaxed 
pBR322 to its supercoiled form. WT or mutant GyrA was mixed with WT GyrB in a ratio of 
1:1. Each supercoiling reaction contained 500 ng of relaxed pBR322 DNA (TopoGen, Inc) 
and 300 uM gyrases in 1X assay buffer (TopoGen, Inc). The reaction mixtures were 
incubated at 37 °C for 1h. Assays were terminated by the addition of 0.2 volume of the stop 
buffer (TopoGEN) and 1 volume of chloroform-isoamyl alcohol (24:1). The reactions were 
analyzed on 1.0% agarose gels. The gels were stained with ethidium bromide for 30 min and 
then destained in 1X TAE buffer for 1h.  
 
MEC (minimum effective concentration) determinations 
 
 To determine the susceptibility of various gyrases to the inhibitory effect of 
ciprofloxacin, the in vitro supercoiling assay using recombinant gyrases was also performed 
with added ciprofloxacin as descried previously (28). Ciprofloxacin was added into each 
reaction prior to the addition of DNA gyrases. The minimum effective concentration (MEC) 
was defined as the lowest concentration of ciprofloxacin that shows an observable inhibition 
on supercoiling of the plasmid DNA. 
 
Examination of in vivo supercoiling 
  
To determine if the mutations in GyrA changed the DNA supercoiling in 
Campylobacter cells, the shuttle plasmid pRY107 was used as a reporter to monitor the 
relative difference in the levels of DNA supercoiling between the FQS and FQR strains. 
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pRY107, which carries a kanamycin resistance marker (50), was transferred into 62301S2, 
62301R33, 52901-II2, 62301R37, 11168, and 1168CT by conjugation. The conjugates were 
grown in MH broth (Difco) for one day at 42 °C under microaerobic conditions (10% CO2, 
5% O2, and 85% N2), then plasmid DNA was isolated using QIAGEN Plasmid Midi kit 
(Qiagen Inc.) and analyzed by agarose gel electrophoresis in the absence or presence of 
chloroquine diphosphate salt, as described previously (20, 31). Agarose gels (1%) were run 
for 20 h at 2 V/cm in 1 x TAE buffer containing 20 µg/ml of chloroquine and were washed 
for 4 h in distilled water before staining with ethidium bromide. The topoisomers of the 
plasmid DNA from each strain were visualized using a digital imaging system (Alpha 
innotech). The relative amounts of supercoilied vs. relaxed DNA in each sample reflecting 
the level of DNA supercoiling in each strain were determined by densitometry scanning and 
were used to indicate the difference in DNA supercoiling between the FQS and FQR strains. 
 
Cloning and sequence of topA genes 
 
The entire topA gene from C. jejuni 62301S2 and 62301R33 were amplified by PCR 
with the forward primer topA-F and reverse primer topA-R. The forward primer is 286 bp 
upstream of the AUG start codon, and the reverse primer extends 239 bp beyond the UAG 
stop codon of topA. The PCR was performed in a volume of 50 µl containing 100 µM each 
deoxynucleoside triphosphate (dNTP), 200 nM primers, 2.5 mM MgSO4, 100 ng of 
Campylobacter genomic DNA, and 5 U of Taq DNA polymerase (Promega). The cycling 
conditions consisted of an initial polymerase activation step at 94 °C for 5 min, followed by 
35 cycles of 94 °C for 30 seconds, 55 °C for 30 seconds and 72 °C for 3 min, with a final 
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extension at 72 °C for 10 min. The amplified PCR products were purified with the QIAquick 
PCR purification kit (Qiagen) and subsequently sequenced.  
 
Real-time quantitative RT-PCR (qRT-PCR) analysis of topA transcription in FQS and FQR 
Campylobacter 
 
The transcription level of topA in C. jejuni 62301S2 and 62301R33 was compared by 
qRT-PCR as described in a previous work (22). Briefly, total RNA of 62301S2 and 
62301R33 was isolated from overnight cultures by using the RNasy mini kit (QIAGEN) 
according to the manufacturer's instructions. Isolated RNA was further treated with TURBO 
DNA-free (Ambion) to remove DNA contamination. The qRT-PCR reactions were 
conducted using the iScript one-step RT-PCR kit with SYBR green (Bio-Rad). topA-specific 
primers (cj1686c-F1 and cj1686c-R) and primers specific for the Campylobacter 16S RNA 
gene (16SF and 16SR; for normalization) were used for qRT-PCR. Triplicate reactions, each 
in a volume of 20 µl, were performed for each dilution of the RNA template. Thermal cycling 
conditions were as follows: 10 min at 50 °C, 5 min at 60° C followed by 5 min at 95 °C, and 
then 40 cycles of 10 s at 95 °C and 30 s at 55 °C (for 16S RNA) or 56 °C (for topA). Cycle 
threshold values were determined with the MyiQ software (Bio-Rad). The relative changes 
(n-fold) in topA transcription between the S3B 62301S2 and 62301R33 were calculated using 
the 2−ΔΔCT method as described by Livak and Schmittgen (23). 
 
Antibiotic susceptibility test  
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The minimum inhibitory concentration (MIC) of CIPRO was determined by using E-
test strips (AB Biodisk, Solna, Sweden) following the manufacturer's instructions. The 
maximum detection limit of the E-test for CIPRO was 32 µg/ml.  
 
Campylobacter motility assay 
 
Campylobacters were grown overnight on fresh MH plates and then were collected 
using MH broth. The optical density at 600 nm (OD600) was adjusted to 0.3. Approximately 1 
µl of this suspension was then stabbed into a MH motility plate (MH broth+0.4%Bacto 
Agar). The low density of the agar allows the bacteria to move within the agar, forming a 
halo of growth around the point of inoculation. Following microaerobic growth at 42 °C for 
approximately 30 h, the radius of the ring was measured relative to that of the ring produced 
by the control strain.  
 
GenBank Accession No.  
 
The assigned GenBank accession no. for topA in strain 62301S2 and 62301R33 is 
FJ795047. 
 
4. Results 
 
Role of the Thr-86-Ile change in enhanced fitness 
 
Our previous study showed that FQR Campylobacter carrying the C257T mutation 
(leading to a Thr-86-Ile substitution in the GyrA subunit) outcompeted its isogenic FQS 
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strains in chickens, suggesting that acquisition of FQ resistance enhances the in vivo fitness 
of FQR Campylobacter. To further confirm the link of this specific mutation with the 
enhanced fitness, we reverted the mutation back to the wild-type allele and conducted 
pairwise competition in chickens using 62301R33S and 62301R33R. After inoculation with 
either of the two isolates or mixed populations, all of the groups of birds were colonized by 
Campylobacter at similar levels (Fig. 1A). When separately inoculated into chickens, the two 
strains showed no significant differences (P > 0.05) in the level of colonization (the number 
of Campylobacter shed in feces) (Fig. 1A). Differential plating by using ciprofloxacin-
containing plates showed that the group inoculated with the FQS revertant alone shed 
homogeneous FQS Campylobacter, whereas the group inoculated with FQR strain shed 
homogeneous FQR Campylobacter during the entire course of the experiment. However, in 
the group inoculated with mixtures of the two strains, the FQS revertant strain was 
outcompeted by its parent FQR Campylobacter (P < 0.05) (Fig. 1B). Testing of randomly 
selected Campylobacter colonies (10~15 colonies per group per time point) by using Etest 
confirmed the results of differential plating. This result clearly indicates that once the C257T 
mutation in gyrA is reverted, Campylobacter loses its fitness advantage in chickens, 
confirming our previous results using clonally related and isogenic strains (26). To further 
show the specific effect of the C257T mutation on fitness, we introduced this mutation into a 
different strain background (NCTC 11168) and conducted chicken competition using the 
isogenic pair of constructs. As shown in Fig 1C, 11168(S) was outcompeted by 11168(R) (P 
< 0.05), indicating the mutation had the same impact on fitness in a C. jejuni strain different 
from the previously tested ones. These new findings plus our published studies (26) 
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convincingly showed that the C257T mutation in gyrA is directly responsible for the 
enhanced fitness of Campylobacter in chickens. 
 
No compensatory mutations in topA.  
 
C. jejuni has only two types of topoisomerases, type I (TopA) and type II (gyrase). 
The gyrase introduces negative supercoiling to DNA, while TopA relaxes DNA to prevent 
excessive supercoiling. Thus, the two enzymes are the key proteins modulating the level of 
DNA supercoiling in Campylobacter. Previously we demonstrated that isolate 62301R33 
(FQR), which carried the Thr-86-Ile mutation and outcompeted FQs Campylobacter 
(62301S2) in chickens, did not harbor any compensatory mutations in GyrA and GyrB (26). 
In this study, we sought to determine if there were any mutations in TopA that might 
potentially offset the impact of the Thr-86-Ile mutation in GyrA. The whole ORF of topA 
was PCR amplified from 62301R33 and sequenced, which showed that the topA sequence 
was identical to that in 62301S2. In addition, the expression level of topA in 62301R33 and 
62301S2 were compared by qRT-PCR, which did not reveal a significant difference. These 
results suggest that the Thr-86-Ile mutation in GyrA was not accompanied by changes in 
topA sequence or expression.  
 
Effect of GyrA mutations on in vitro supercoiling.  
 
To determine the impact of the resistance-conferring mutations on the enzymatic 
activities of GyrA, we produced the recombinant forms of various gyrases. As estimated by 
SDS-PAGE, the recombinant GyrA and GyrB were 97 kDa and 87 kDa, respectively, 
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comparable with the calculated molecular masses of the two proteins (Fig. 2A). The mutant 
GyrA carrying Thr-86-Ile, Thr-86-Lys, or Asp-90-Asn mutation migrated at the same 
position as the wild-type GyrA on the SDS-PAGE (data was not shown), indicating that the 
point mutations in GyrA did not change its migration on SDS-PAGE. The supercoiling 
activity of the WT and mutant DNA gyrases was analyzed in vitro by using the recombinant 
proteins. Both GyrA and GyrB are required for supercoiling the plasmid DNA and no 
detectable activity was observed when only GyrA or GyrB was used in the assay (data were 
not shown). The mutant GyrA carrying the Thr-86-Lys or Asp-90-Asn mutation exhibited 
supercoiling activities comparable to that of the WT GyrA, whereas the supercoiling activity 
of the mutant GyrA carrying the Thr-86-Ile change was substantially reduced comparing to 
that of the wild-type GyrA. In fact, the most supercoiled band was absent with this mutant 
GyrA (Fig. 2B). The results were consistently shown in multiple experiments with different 
concentrations of gyrases (up to 1200 nM; data were not shown).  
 
Effect of the GyrA mutations on in vivo supercoiling 
 
 The recombinant mutant GyrA with the thr-86-Ile mutation showed reduced 
supercoiling activity in vitro, but it is important to know if the same mutation also affects 
DNA supercoiling in vivo (in Campylobacter cells). For this purpose, we used the shuttle 
plasmid pRY107 as a reporter plasmid to monitor the relative levels of DNA supercoiling in 
the FQS and FQR strains. The plasmid pRY107 was transferred into 62301S2 (wild-type 
strain), 62301R33 (carrying the Thr-86-Ile mutation in GyrA), 52901-II2 (carrying the Thr-
86-Lys mutation in GyrA), and 62301R37 (carrying the Asp-90-Asn mutation), which were 
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clonally related and all derived from strain S3B (26). Plasmid DNA was re-isolated from 
these constructs and analyzed by agarose gel electrophoresis in the presence of chloroquine. 
Under the condition utilized in this study (20 µg /ml chloroquine), negatively supercoiled 
forms migrated slower than relaxed topoisomers, which was confirmed by negatively 
supercoiled plasmid pBR322 and relaxed plasmid pBR322 (results not shown). Compared to 
the pRY107 from 62301S2, the plasmid topoisomers from 62301R33 harboring the Thr-86-
Ile mutation in GyrA shifted to lower positions, indicating less supercoiling (Fig. 3A). As 
determined by densitometrical analysis, the percentage of the most supercoiled DNA in the 
total population of the plasmid topoisomers extracted from 62301S2 and 62301R33 was 
87.4% and 20.2%, respectively. The plasmids from 52901-II2 and 62301R37 showed 
topoisomer distribution patterns similar to that of 62301S2 (Fig 3A). These results indicate 
that the GyrA mutant with the Thr-86-Ile mutation reduced DNA supercoiling in 
Campylobacter cells, while the mutants with the Thr-86-Lys or Asp-90-Asn changes in GyrA 
did not alter DNA supercoiling. To further confirm the impact of the Thr-86-Ile change on 
DNA supercoiling, we introduced pRY107 to a different strain background, NCTC 11168 
and 11168CT. The only known difference between this pair of isolates is the C257T mutation 
in gyrA. Similar to the result from 62301R33, the plasmid topoisomers from 11168CT shifted 
to lower positions compared with NCTC 11168 (Fig 3B). Together, the in vivo supercoiling 
results were consistent with the findings from the in vitro supercoiling assay and indicated 
that the Thr-86-Ile mutation reduced DNA supercoiling in Campylobacter. 
 
GyrA mutations reduce the susceptibility to ciprofloxacin 
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The effects of ciprofloxacin on the supercoiling activity of Campylobacter DNA 
gyrases were determined using the in vitro supercoiling assay. As shown in Fig. 4, the MECs 
of CIPRO to wild-type GyrA and the two mutants GyrA carrying the Thr-86-Lys or Asp-90-
Asn change were 32 and 1024, respectively, indicating the two mutations significantly 
reduced the susceptibility of GyrA to the inhibition by CIPRO. With the mutant GyrA 
carrying the Thr-86-Ile change, the inhibitory effect of CIPRO was not measurable because 
the mutation itself abolished the ability of the enzyme to form the supercoiled band in the in 
vitro assay (Fig. 4). These findings provide a molecular basis for the reduced susceptibility of 
FQR mutants to CIPRO.  
 
5. Discussion 
 
Antibiotic resistance-associated mutations often affect the physiological functions in 
bacteria and may impose a biological cost in the absence of antibiotics. The fitness cost 
associated with topoisomerase mutations has been reported in several bacteria (4, 14, 20, 51). 
In Salmonella  typhimurium, the FQR mutants selected in vitro or in vivo (chicken) showed 
different growth characteristics in culture medium and in the chicken host in the absence of 
FQs (14). The S. typhimurium mutants selected by in vitro plating were highly resistant to 
FQs, but grew significantly slower in culture medium and on solid media, and failed to 
colonize chickens. On the contrary, the in vivo selected resistant isolates exhibited 
intermediate susceptibility to FQs, had normal growth in liquid medium, and were able to 
colonize chickens as efficiently as or lower than that of the wild-type strains (14, 51). In the 
case with FQR E. coli, single mutations in DNA gyrase or topoisomerase IV confer low-level 
resistance to FQs, while accumulation of multiple mutations in the enzymes result in high-
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level resistance (4, 32). Interestingly, the single mutations were not associated with fitness 
reduction, but the mutants carrying multiple mutations showed a significant fitness 
disadvantage when assayed in competition experiments in vitro and in a mouse model (19). 
These findings suggest that resistance-conferring GyrA mutations generally impose a fitness 
cost in bacterial pathogens. 
 
In contrast to the findings in other bacteria, our previous study using clonally related 
isolates and isogenic mutants generated by natural transformation showed that FQR 
Campylobacter isolates outcompeted the FQS strains in chickens in the absence of FQ 
antimicrobials and the enhanced fitness was linked to the single point mutation (C257T) in 
gyrA, which confers on Campylobacter a high-level resistance to FQ antimicrobials (26). In 
the previous study, the isogenic mutants were generated by natural transformation and 
ciprofloxacin was used to select for the isogenic transformants. There was a concern that 
ciprofloxacin might also have selected for spontaneous FQR mutants with unknown 
compensatory mutations that could affect the fitness of Campylobacter. To address this 
concern, we further defined the role of the Thr-86-Ile mutation in GyrA in enhanced fitness 
by reverting the mutation back to the wild-type allele. In the creation of the revertant, a Cmr 
cassette, which was inserted into cj1028c upstream of gyrA, was used as selective marker to 
revert the mutant gyrA allele by homologous recombination. This strategy allowed us to test 
if a compensatory mutation was involved in the enhanced fitness of the FQR mutants. The in 
vivo fitness study showed that once the Thr-86-Ile mutation in GyrA of 62301R33 was 
reverted, Campylobacter lost its fitness advantage in chickens, confirming the specific effect 
of the point mutation on fitness. In addition, introducing the Thr-86-Ile mutation into the 
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GyrA of the wild-type strain NCTC11168, which is divergent from S3B derivatives used in 
our previous work (26), also enhanced its fitness in chickens. Together, these findings 
conclusively establish that the C257T mutation in gyrA enhances fitness of C. jejuni in 
chickens.  
 
How the Thr-86-Ile mutation affects Campylobacter fitness remains a question and 
was the main reason for performing in this study. Gyrase introduces and maintains negative 
supercoils in DNA, which is important for DNA replication and transcription. Thus, 
resistance-conferring mutation in GyrA may affect its enzymatic function. Indeed, it has been 
shown in other bacteria that antibiotic resistance-conferring mutations in GyrA affected the 
supercoiling activity of the enzyme (5, 20). A previous study conducted by Barnard et. al. 
showed that a FQR E. coli mutant carrying single (Ala87) or double mutations (Ala83 Ala87) in 
GyrA exhibited reduced supercoiling compared to that of the wild type (5). In Pseudomonas 
aeruginosa, it was also shown that a FQR GyrA Ile83 mutant and a Tyr87 mutant had 
decreased supercoiling, which was associated with reduced growth rate (20). In this study, 
we demonstrated that in Campylobacter the Thr-86-Ile change in GyrA resulted in a greatly 
reduced supercoiling activity compared to that of the wild-type enzyme (Fig. 2). The change 
in the enzymatic activity was further confirmed by the reduced supercoiling status in 
Campylobacter cells (Fig. 3). These findings suggest that development of FQ resistance 
impacts DNA supercoiling homeostasis within Campylobacter. Despite this effect, FQR 
Campylobacter grow well in vitro, can colonize and persist in chickens as efficiently as the 
FQS strains in the absence of antibiotic usage when monoinoculated into the chickens, and 
can outcompete the FQS parent strains when coinoculated into chickens.  
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In contrast to the Thr-86-Ile mutation, the supercoiling activity of the mutant gyrases 
harboring the Thr-86-Lys or Asp-90-Asn mutation was comparable to that of the wild-type 
gyrase (Fig. 2), indicating that these two types of mutations did not affect the function of the 
enzyme. Interestingly, the Thr-86-Ile and Thr-86-Lys mutations occurred at the same place, 
but had a different impact on the enzyme function. This is probably due to the fact that Ile 
and Lys have different chemical properties. Ile is aliphatic, hydrophobic and neutral, while 
Lys is polar, hydrophilic, and positively charged. In Campylobacter GyrA, Thr-86 is 
equivalent to Ser-83 in Escherichia coli GyrA(47). It has been known that Ser-83 is located 
in the QRDR region , which are situated close to the catalytic cleavage residues Tyr122 , and 
Ser-83 has an important role in the interaction of gyrase-quinolone-DNA complex (5). Thus 
changes at Ser-83 (Thr-86 in Campylobacter) can conceivably prevent FQ binding, but is 
also accompanied by altered supercoiling activities of the gyrase. 
 
The results presented in this study strongly indicate that the Thr-86-Ile mutation 
impacts DNA supercoiling in Campylobacter. It would be interesting to know if FQR mutants 
acquire compensatory mutations to offset the impact of the Thr-86-Ile mutation. In 
Campylobacter, the genes encoding topoisomerase IV (parC/parE) are absent (36), and 
supercoiling homeostasis is controlled by topoisomerase I (TopA) and topoisomerase II 
(GyrA and GyrB). Our previous study has shown that the FQR isolates had no compensatory 
mutations in GyrA and GyrB (26). Since topoisomerase I, encoded by topA gene, is involved 
in the relaxation of DNA supercoiling and also has an important role in the maintaining of 
the topological state of DNA, it is necessary to see if there is any compensatory mutation in 
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topA and whether the expression of the topA is changed that contributes to the enhanced 
fitness. Our studies showed that the primary sequences of topA gene were identical for 
62301S2 and 62301R33 and there was no difference in the expression of topA between these 
two strains, which excludes the possibility that mutations or altered expression of 
topoisomerase I is involved in the fitness change associated with FQR Campylobacter. 
 
The MIC is the lowest concentration of an antimicrobial that inhibits the visible 
growth of a microorganism after incubation, while the MEC is the lowest concentration of a 
drug that shows any inhibition of supercoiling activity (15). In this study, we demonstrated 
that the mutant gyrases carrying the Thr-86-Lys or Asp-90-Asn mutation had significantly 
higher MECs of CIPRO than the wild-type GyrA, indicating the mutant gyrases are more 
resistant to CIPRO. Interestingly, the MECs of CIPRO with the enzymes were significantly 
(at least 250 times) higher than the MICs of CIPRO in these strains. This finding was 
consistent with the results from other studies (15, 29) that MECs and MICs differ by one or 
two orders of magnitude. The in vitro results (Fig. 4) provide a molecular explanation for the 
resistance of FQR Campylobacter mutants to FQ antimicrobials. 
 
To our knowledge, this is the first report that a FQR-conferring mutation in gyrase 
reduces its supercoiling activity, but enhances the fitness of the mutant strain. This result is in 
contrast to the results from a recently published paper (20), in which reduced fitness of FQR 
mutants of Pseudomonas aeruginosa was associated with decreased DNA supercoiling. 
Usually decreased supercoiling causes an increased accumulation of positive supercoils in 
front of a replication/transcription, which in turn reduce the growth rate (20). This apparently 
 
 
 
114 
did not happen with FQR Campylobacter because it grows as efficiently as FQS 
Campylobacter in both culture media and animal hosts. The intriguing question is whether 
the reduced supercoiling activity of the gyrase affects Campylobacter physiology and 
directly contributes to the enhanced fitness in chickens. DNA supercoiling is important for 
gene expression, and it is possible that the change in DNA supercoiling homeostasis affects 
the expression of certain genes in Campylobacter. This possibility remains to be investigated 
in future studies. 
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Table 1. Bacterial strains used in this study 
Table 1 Bacterial strains used in this study 
 Strains aa mutation in GyrA nt mutation in GyrA 
62301S2 None None 
52901-I 1 None None 
62301R33S None None 
NCTC 11168 None None 
FQS strains 
11168 (S) None None 
62301R33 Thr-86-Ile C257T 
52901-II 1 Thr-86-Lys C257A 
FQR strains 
62301R37 Asp-90-Asn G268A 
 62301R33R Thr-86-Ile C257T 
 11168CT  Thr-86-Ile C257T 
 11168 (R) Thr-86-Ile C257T 
 
 
 
 
121 
Table 2. Key PCR primers used in this study 
Table 2 Key PCR primers used in this study 
Primer name  Sequence (5'-3') Target gene/cluster 
gyrA1028F  TGCTCTGCTTTTGTGAATTA 
gyrA257WR  AAACTGCTGTATCTCCATGT 
Cj1028c and gyrA 
(ACA, Thr-86) 
   
gyrA1028F  TGCTCTGCTTTTGTGAATTA 
gyrA257m (T)  AAACTGCTATATCTCCATGT  
Cj1028c and gyrA 
(ATA, Ile-86) 
   
gyrA-F-2  ACATGCATGCGAGAATATTTTTAGCAA 
gyrA-R  ACGCGTCGACTTATTGCAAATCTAAACC 
whole ORF of gyrA 
   
gyrB-F-J2  ACATGCATGCCAAGAAAATTACGGTGCG 
gyrB-R-J  ACGCGTCGACTTACACATCCAAATGCTT 
whole ORF of gyrB 
   
topA-F  GCTGCTTTAAATCCGGACTT 
topA-R  CAGCTTCGCAAACATACTCA 
whole ORF of topA 
   
cj1686c-F1 AAGCCAAAGATGCCAAAGAA 
cj1686c-R1 TGCGTGGTAAGGTGTTTTCA 
topA  
   
16SF TACCTGGGCTTGATATCCTA 
16SR GGACTTAACCCAACATCTCA 
16S RNA 
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Fig. 1 Pairwise competition between FQS and FQR strains in chickens 
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Fig. 1. Pairwise competition between FQS and FQR strains in chickens. (A) The level of total 
Campylobacter in each chicken inoculated with 62301R33S (solid circle), 62301R33R (open 
circle), or 1:1 mixture of the two stains (half solid half open circle). (B) Differential 
enumeration of FQS (solid circle) and FQR (open circle) Campylobacter in the group 
inoculated with a mixture of 62301R33S and 62301R33R (left panel) and competition index 
of the competitive fitness (right panel). (C) The level of FQS (solid triangle) and FQR (open 
triangle) Campylobacter in the second chicken experiment in which the chickens were 
inoculated with a 1:1 mixture of 11168(S) and 11168(R) (left panel) and competition index 
of the competitive fitness (right panel). The mean colonization level of each group at a given 
time is indicated by a horizontal bar. The detection limit of the plating method is about 100 
CFU/g of feces. DAI: days after inoculation. 
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Fig. 2 SDS-PAGE analysis of purified recombinant GyrA and GyrB & Supercoiling 
activities of the WT gyrase and the three mutant gyrases measured by an in vitro assay 
Fig. 2. (A) SDS-PAGE analysis of purified recombinant GyrA and GyrB. Lane 1, Purified 
GyrB; Lane 2, Purified WT GyrA; Lane3, Purified mutant GyrA (T86I); and Lane M, protein 
size markers. (B) Supercoiling activities of the WT gyrase and the three mutant gyrases 
measured by an in vitro assay. Lane 1, DNA ladder; Lane 2, relaxed pBR322 (control); Lane 
3, WT GyrA+GyrB; Lane 4, mutant GyrA(T86I)+GryB; Lane 5, mutant GyrA(T86K)+GryB; 
Lane 6, mutant GyrA(D90N)+GryB; and Lane 7, supercoiled pBR322 (control). SC indicates 
supercoiled DNA and R represents relaxed DNA. 
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Fig. 3 Agarose gel electrophoresis analysis of plasmid topoisomers extracted from different 
strain background 
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Fig. 3. Agarose gel electrophoresis analysis of plasmid topoisomers extracted from different 
strain backgrounds. The plasmid DNA was run on a 1.0% agarose gel containing 20 µg /ml 
chloroquine. (A) Plasmid pRY107 isolated from strain S3B derivatives. Lane1, pRY107 from 
62301S; Lane 2, pRY107 from 62301R (Thr-86-Ile mutation in GyrA); Lane 3, pRY107 
from 52901-II2 (T86K mutation in GyrA); and Lane 4, pRY107 from 62301R37 (D90N). (B) 
Plasmid pRY107 isolated from strain 11168 backgrounds. Lane 1, pRY107 from NCTC 
11168 and Lane 2, pRY107 from 11168CT (T86I mutation in GyrA). The results of 
densitometric scanning are shown to the right of each gel image. The numbers on the left of 
the densitometric scanning correspond to the lane numbers of the gel image. The number 
below each lane indicates the percentage of the most supercoiled DNA in the total population 
of plasmid topoisomers as measured by densitometry. 
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Fig. 4 Inhibition of DNA gyrase supercoiling activity by ciprofloxacin as measured by an in 
vitro supercoiling assay 
Fig. 4. Inhibition of DNA gyrase supercoiling activity by ciprofloxacin as measured by an in 
vitro supercoiling assay. A, WT GyrA+GyrB; B, mutant GyrA (Thr-86-Lys)+GyrB; C, 
mutant GyrA (Asp-90-Asn)+GyrB; and D, mutant GyrA (Thr-86-Ile)+GyrB. The numbers 
on the top of each panel are the concentraction of ciprofloxacin (μg/ ml) used in the reaction. 
SC indicates supercoiled DNA and R represents relaxed DNA. 
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1. Abstract 
 
Our previous work showed that acquisition of fluoroquinolone (FQ) resistance via a 
specific GyrA mutation (Thr-86-Ile) enhances the in vivo fitness of FQ-resistant mutants in 
the absence of antibiotic selection pressure and the Thr-86-Ile change in GyrA both confers a 
high-level resistance to FQs and significantly reduces the supercoiling activity of the enzyme 
in Campylobacter. To understand how the reduced supercoiling activity of mutant DNA 
gyrase affects Campylobacter fitness, we initiated work to determine if this altered 
supercoiling activity affects the gene transcription and protein expression in the bacterial 
organisms. Using both DNA-microarray and 2-D DIGE (two dimensional differential in-gel 
electrophoresis) methods, we compared the transcription patterns and protein profiles 
between the FQR and FQS Campylobacter grown in laboratory media. Results revealed that 
the expression of multiple genes was changed in FQR strains compared to FQS stains. 
Notably, the iron-response system and proteins involved in energy metabolism were 
upregulated in FQR Campylobacter, which may contribute to its enhanced fitness in the 
chicken host.  
 
 
2. Introduction 
 
Campylobacter jejuni is a major foodborne pathogen worldwide and causes diarrhea, 
abdominal pain, colitis and other clinical diseases in humans (40). Clinically, Campylobacter 
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infections are mild, self-limiting and usually resolve within a few days. No specific treatment 
is required for most patients with Campylobacter enteritis, but antibiotic treatment is needed 
in severe cases or in immunocompromised patients (2, 8, 9, 11, 14, 35). Fluoroquinolones 
(FQs) or erythromycin are the antibiotics of choice for treating Campylobacter infection (14, 
35). However, Campylobacter has become increasingly resistant to FQs worldwide over the 
past 15 years, which is a major concern for public health (14, 21, 34, 45). Although FQ 
antimicrobials have been banned since 2005 in poultry production in the U.S., FQ-resistant 
(FQR) Campylobacter continues to persist in poultry farms (29, 37, 38).  
 
In Campylobacter, resistance to FQs is mediated by a point mutation in the quinolone 
resistance-determining region (QRDR) of gyrA in conjunction with the function of the 
multidrug efflux pump CmeABC (6, 14, 17, 31). Usually antibiotic resistance-conferring 
mutations in target genes are associated with changes in physiological processes, resulting in 
reduced growth rate and fitness in the absence of antibiotic selection pressure (5). However, 
in Campylobacter FQR mutants carrying the Thr-86-Ile change in the GyrA subunit of DNA 
gyrase were able to colonize and persist in chickens as efficiently as the FQ-susceptible (FQS) 
strains in the absence of FQ and showed enhanced fitness in chickens. This altered phenotype 
was directly linked to the resistance conferring mutation and was confirmed by using 
isogenic mutants as well as revertants (30).  
 
DNA gyrase plays an essential role in maintaining the topological configuration of 
DNA by introducing negative superhelical turns in DNA. Our previous study has shown that 
the Thr-86-Ile mutation in GyrA greatly reduced the supercoiling activity of DNA gyrase 
both in vitro and in vivo (within Campylobacter cells). Whether the changed supercoiling 
function of the mutant gyrase is responsible for the enhanced fitness is unknown. It has been 
well established that DNA supercoiling affects gene transcription in bacterial organisms (1). 
DNA supercoiling is a key player in regulating bacterial adaptive responses to environmental 
challenges such as stress. A number of studies have shown that changes in environmental 
conditions such as temperature, osmolarity, and oxidative stress affect DNA supercoiling and 
consequently alter the expression of a number of genes involved in the adaptation to the 
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changes (12, 42). DNA topological changes are also linked to intracellular adaptation, 
expression of virulence factors such as surface proteins, and invasins of pathogenic 
organisms (3, 15, 32). In E.coli, alteration of DNA supercoiling by mutations in TopA and 
GyrB affects the relative abundance of more than 80 proteins (41). Based on the available 
evidence, we hypothesize that the reduced supercoiling activity of mutant DNA gyrase (Thr-
86-Ile mutation in GyrA) alters gene expression in the Campylobacter cells, which 
contributes to the enhanced in-host fitness. 
 
To examine our hypothesis, we used whole-genome microarray to compare the 
transcription patterns in FQS and FQR strains. Microarray results identified 23 genes with 
≥1.5-fold (p <0.05) changes in expression, among which 17 were up-regulated and 5 were 
down-regulated in FQR mutant (62301R33) compared with FQS (62301S2). In addition, we 
conducted 2-D DIGE (two dimensional differential in-gel electrophoresis) to compare the 
protein profiles of FQR (62301R33R) and FQS (62301R33S) Campylobacter. The 2-D DIGE 
results revealed 42 protein spots that were significantly differentially expressed in 
62301R33R compared with 62301R33S, among which 39 were up-regulated and 3 were 
down-regulated. Ten spots of interest were identified by MALDI-TOF/TOF. 
 
3. Materials and Methods 
 
Bacterial strains and growth conditions 
 
The various Campylobacter strains used in this study are listed in Table 1. The 
Campylobacter strains were routinely grown in Mueller-Hinton (MH) broth (Difco) or on 
MH agar plates at 42°C under microaerobic conditions (10% CO2, 5% O2, and 85% N2).  
 
Bacterial RNA isolation 
 
Campylobacter isolates 62301S2 and 62301R33 were grown in MH broth for 48 
hours (OD600 ≈ 0.45) and were immediately treated with 2 volumes of RNAprotect Bacterial 
Reagent (Qiagen, Valencia, CA) to stabilize the total bacterial RNA. After incubation for 10 
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min at room temperature, the culture was centrifuged at 10,000 × g for 10 min. Bacterial 
RNA was isolated using an RNeasy Mini Kit (Qiagen) according to the manufacturer's 
instructions. Isolated RNA was treated with an on-column DNase Digestion Kit (Qiagen), 
which was followed by removal of the DNase using an RNeasy Mini Kit (Qiagen). The 
absence of DNA contamination in the RNA samples was confirmed by reverse transcription-
PCR (RT-PCR). The concentration of total RNA was estimated with the NanoDrop ND-1000 
spectrophotometer (NanoDrop, Wilmington, DE, USA), and the integrity and size 
distribution of the purified RNA was determined by denaturing agarose gel electrophoresis 
and ethidium bromide staining. The quality of total RNA was further analyzed using the 
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), which showed the 
good quality and integrity of the RNA samples (Data not shown). The purified RNA was 
kept at −80 °C until it was used. RNA samples extracted from three independent experiments 
were used for the microarray hybridization experiments. 
 
cDNA synthesis and labeling 
 
cDNA synthesis and fluorescence labeling were performed using ChipShot™ Indirect 
cDNA Labeling and Clean-Up Protocols (Promega) according to the manufacturer's 
instructions. Briefly, 5µg of total RNA was reverse transcribed using ChipShotTM reverse 
transcriptase, random primers and Oligo(dT) primers in the presence of an aminoallyl-dNTP 
mix together with 5X reaction. After incubation at 42°C for 2 hours, RNase H was added to 
the reaction mix to degrade RNA. The synthesized aminoallyl-cDNA was purified using 
ChipShot™ Membrane columns (Promega) to remove unincorporated nucleotides and eluted 
with 65µl of 100mM sodium bicarbonate (pH 9.0). Sixty µl purified aminoallyl cDNA were 
then labeled by coupling with one dried aliquot of post-labeling CyDye™ NHS ester, Cy3 or 
Cy5 (GE Healthcare Bio-Sciences). A final purification step using ChipShot™ Membrane 
Columns (Promega) removed unreacted dyes, and the amount of labeled cDNA was 
estimated with the NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, 
USA). The pmol of dye incorporated and the frequency of incorporation (FOI) were 
calculated accordingly. The eluted cDNA with good quality was stored in a lightproof 
container at 4 °C until it was used to hybridize microarray slides.  
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Microarray hybridization 
 
C. jejuni NCTC 11168 microarray slides were purchased from Ocimum Biosolutions. 
The array contained 1,632 oligonucleotide (50-mer) probes covering the entire transcriptome 
of NCTC 11168. To compare the gene expression of FQR strain (C257T mutation in gyrA) 
with that of FQS strain, equal volumes of Cy3- or Cy5-labeled cDNAs from the 62301S2 
strain and 62301R33 strain were combined and dried with a SpeedVac and then resuspended 
in 120 µl of hybridization buffer (Ocimum Biosolutions). The probes were denatured at 95°C 
for 3 min, briefly cooled on ice, and then hybridized to the microarray slide using microarray 
gene frames (Ocimum Biosolutions). The slide were placed in a wet hybridization chamber 
and incubated on a shaker for 20 h at 42°C. After hybridization, the slide was washed 
sequentially with wash buffer 1 (2x SSC, 0.1 % SDS) for 10 min, wash buffer 2 (1 x SSC) 
for 10 min, and wash buffer 3 (0.1 x SSC) for 10min. Each wash step was repeated three 
times. The washing buffers were prewarmed at 32°C, and all of the washing steps were 
performed at 32°C. Finally, the slides were dried by centrifugation at 500 × g for 3 min. The 
microarray slides were hybridized with the swaped-dye labeled cDNA samples to ensure dye 
balance in the experimental design. The hybridization experiments were performed using 
RNA extracted from three biological replicates and each of the experiments consisted of two 
technical replicates (slides). 
 
Data collection and analysis 
 
Hybridized slides were scanned at a wavelength of 650 nm for Cy5 and at a 
wavelength of 550 nm for Cy3 using a General Scanning ScanArray 5000 (PerkinElmer, 
Boston, MA) at 10 µm resolution. The fluorescence intensities were collected with the 
ImaGene software (BioDiscovery, El Segundo, CA). Genes with fluorescence signals within 
less than 2 standard deviations of the background were considered insignificant. Background 
subtraction, Lowess normalization, scale normalization, and median centering were 
performed using the R statistical package (version 2.0.1; The R Foundation for Statistical 
Computing) and the normalized data were subjected to a mixed-linear model analysis using 
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the SAS statistical package. For this study, we chose a P value of < 0.05 and a change equal 
to or greater than 1.5-fold as the cutoff for significant differential expression in comparisons 
of the FQR and FQS strains. 
 
Real-time quantitative PCR (qRT-PCR) 
 
Representative genes identified by the DNA microarray were further confirmed by 
Real-time quantitative PCR (qRT-PCR) as described in a previous work (27). Before being 
used for quantitative reverse transcriptase PCR (RT-PCR), all RNA templates and primer 
sets were tested with a conventional One-step RT-PCR Kit and a regular PCR kit (Invitrogen) 
to ensure specific amplification from the target mRNA and no detectable DNA 
contamination in the RNA preparation. The RT-PCRs were conducted using the iScript one-
step RT-PCR kit with SYBR green (Bio-Rad). Thermal cycling conditions were as follows: 
10 min at 50°C, 5 min at 60°C followed by 5 min at 95°C, and then 40 cycles of 10 s at 95°C 
and 30 s at 58°C. Samples were normalized using 16S RNA as an internal standard. Cycle 
threshold values were determined with the MyiQ software (Bio-Rad). The relative changes 
(n-fold) of specific genes between the FQR and FQS samples were calculated using the 2−ΔΔCT 
method as described by Livak and Schmittgen (28). Three independent PCR experiments 
were performed to get the mean of the fold change.  
 
Proteome analysis by 2-D DIGE 
 
2-D DIGE was performed by Applied Biomics (Hayward, CA). Briefly, overnight 
fresh bacterial cells 62301R33S and 62301R33R were harvested form MH plates and 
centrifuged. The cell pellets were washed with PBS 4 times and then were dissolved in 2-D 
lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS and 30 mM Tris-HCl, pH 8.5). The samples 
were stored at -80 °C until they were shipped on dry ice to Applied Biomics (Hayward, CA) 
for proteomic analysis. Total protein was extracted from lysed cells and equal amount of 
protein extract from 62301R33S and 62301R33R were labeled with the Cy3 or Cy5 dyes, 
(GE Healthcare, Piscataway, NJ) respectively. The labeled protein extracts were mixed and 
subjected to a single 2-D gel electrophoresis, using isoelectric focusing (IEF) in the first 
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dimension and SDS polyacrylamide gel electrophoresis (SDS-PAGE) in the second 
dimension. After electrophoresis, the gel was scanned using a Typhoon Image Scanner (GE 
Healthcare, Piscataway, NJ). Each scan revealed one of the CyDye signals (Cy3 and Cy5). 
Scanned images were analyzed by Image Quant Software (version 5.0, GE Healthcare) and 
then subjected to in-gel analysis using the DeCyder software (version 6.5, GE Healthcare). 
The ratio change for differentially expressed protein spots was obtained from the in-gel 
DeCyder software analysis. Protein spots of interest were picked up by Ettan Spot Picker 
(GE Healthcare) following the DeCyder software analysis and spot picking design. The 
selected protein spots were subjected to the in-gel trypsin digestion, peptides extraction, 
desalting and followed by mass spectrometry (MALDI-TOF/TOF) (ABI 4700, Applied 
Biosystems, CA). Peptide sequence information was used for protein identification in the 
NCBInr databases.  
 
SDS-PAGE and Immunoblotting 
 
To prepare whole-cell lysates, overnight culture of 62301S2 and 62301R33 were 
grown in MH broth to late logarithmic phase (about 3 x 109 cells/ml), harvested by 
centrifugation, and solubilized by boiling for 10 min in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. Approximately 108 whole 
cells were loaded in each lane and separated by SDS-PAGE with a 12% (wt/vol) 
polyacrylamide separating gel. After SDS-PAGE, the gels were equilibrated for 30 min in the 
transfer buffer (0.025 M Tris base and 0.192 M glycine with 20% methanol; pH 8.3). Proteins 
in the gels were then electrophoretically transferred to nitrocellulose membranes (Bio-Rad) at 
60 V for 1 h on ice. The membranes were incubated with blocking buffer (5% Nestle skim 
milk powder in PBS) for 4 h at 4°C prior to incubation with anti-FlaA. After incubation at 
room temperature for 1 h, the blots were washed three times with PBS containing 0.05% 
Tween 20 and subsequently incubated with secondary antibodies (goat anti-rabbit 
immunoglobulin G-horseradish peroxidase; Kirkegaard & Perry) at room temperature for 1 h. 
After washing, the blots were developed with the 4 CN Membrane Peroxidase Substrate 
System (Kirkegaard & Perry). Prestained molecular mass markers (Bio-Rad) were 
coelectrophoresed and blotted to allow estimation of the sizes of the proteins. 
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4. Results 
 
DNA microarray identified multiple genes differently expressed in the FQR mutant 
 
To compare the gene transcription patterns in FQS and FQR (Thr-86-Ile) strains, DNA 
microarray was used to analyze the differences in transcriptoms between 62301S2 and 
62301R33. The two strains are clonally related and were well characterized in terms of 
genotypic and phenotypic characteristics (30). Microarray results showed 23 genes with 
≥1.5-fold (p <0.05) changes in expression, among which 17 were up-regulated (Table 2) and 
5 were down-regulated in FQR mutant (62301R33) compared with FQS (62301S2).  
 
Notably, 11 (indicated by an asterisk in Table 2) of the 17 upregulated genes are 
known Campylobacter genes whose expression is increased in iron-limited conditions (24, 
36). ChuA (Cj1614) which functions as a haemin receptor involved in iron uptake (43). 
Cj1613c encodes an orthology (39% aa identity) of HugZ, which is involved in heme iron 
utilization (20, 23, 43). ExbB1 (Cj0179) is a biopolymer transport protein. Cj1661 and cj 
0176c encode the ferric-binding protein of a putative ABC transport system. Hypothetical 
protein Cj0427 co-transcribed with Cj0426, which is a putative ABC transporter ATP-
binding protein. Ahpc (Cj0334) is an alkyl hydroperoxide reductase. Cj1664 encodes 
putative periplasmic thioredoxin. Both Cj0334 and Cj1664 are involved in the oxidative 
stress response of Campylobacter. Cj1383c and cj1384c are tandemly positioned on the 
Campylobacter chromosome and encode hypothetical proteins of unknown function. Cj0089 
encodes a putative lipoprotein. The other upregulated genes include flaA, which encodes the 
major subunit of flagellum and has an important role in the motility of Campylobacter (18, 
44). Cj1002c encodes a putative phosphoglycerate/ bisphosphoglycerate mutase, which 
catalyzes reactions involving the transfer of phospho groups between the 3 carbon atoms of 
phosphoglycerate. Cj0843c encodes a putative secreted transglycosylase. Cj1626c and 
cj0200c encode putative periplasmic protein. The transcription of 7 genes selected from the 
microarray list was further confirmed by three independent qRT-PCR experiments (Table 2). 
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The down-regulated genes include cj0262c, cj0246c, cj1127c, cj1139c, and cj1180c. 
pglJ  (Cj1127c) is a GalNAc transferase involved in the N-glycan biosynthesis in C. jejuni 
(26). Cj0262c encodes a putative methyl-accepting chemotaxis signal transduction protein. 
Cj0246c encodes a putative MCP (methyl-accepting chemotaxis protein)-domain signal 
transduction protein. Cj1139c encodes a putative galactosyltransferase. Cj1180c encodes a 
putative ABC transporter ATP-binding protein. None of the five down-regulated genes is 
among the ones known to be regulated by iron concentration. 
 
Proteomic analysis of 62301R33S and 62301R33R 
 
2-D DIGE was used to investigate the difference in the protein profiles between 
62301R33S and 62301R33R. Using fold change ≥1.5-fold as cutoff, the Decyder analysis of 
2D-DIGE image revealed 42 protein spots that were significantly differentially expressed in 
62301R33R compared with 62301R33S (Figure 1 and 2), among which 39 were up-regulated 
and 3 were down-regulated (Table 3). Ten spots of interest were identified by MALDI-
TOF/TOF using MASCOT search engines on NCBInr sequence database (Table 4). These 
proteins include flavodoxin (FldA), flagellar hook protein (FlgE), translation elongation 
factor Tu (Tuf), HAD-superfamily hydrolase subfamily IA variant 1 family protein, 
ribosomal proteins L23 and L7/L12, DNA-binding protein HU, F0F1 ATP synthase subunit 
epsilon, and a hypothetical protein. Flavodoxins are electron-transfer proteins that function in 
various electron transport systems. FlgE is a flagellar hook subunit protein. The function of 
the flagellar hook is to connect the filament to the basal body and acts as a joint to transmit 
the rotation of the rod of the basal body to the filament. Elongation factor Tu promotes the 
GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein 
biosynthesis. HAD-superfamily hydrolase, subfamily IA, variant 1 represents part of one 
structural subfamily of the HAD-superfamily of aspartate-nucleophile hydrolases. The 
function of F0F1-ATP synthase, which is composed of membrane-embedded F0-portion and 
hydrophilic catalytic F1-portion, is to couple ATP synthesis/hydrolysis with transmembrane 
proton transport. HU is a histone-like DNA-binding protein that plays an important role in 
bacterial nucleoid organization and is involved in numerous processes including transposition, 
recombination and DNA repair (10, 25). Ribosomal proteins L23 and L7/L12 are 50S 
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ribosomal proteins. L23 is one of the proteins that surrounds the polypeptide exit tunnel on 
the outside of the ribosome and forms the main docking site for trigger factor binding to the 
ribosome. L7/L12 is a stalk proteins that implicated in the ribosomal interaction with the 
translocase (33). 
 
5. Discussion 
 
DNA gyrase plays an essential role in maintaining the topological configuration of 
DNA, which affects gene transcription in bacterial organisms and plays an important role in 
regulating bacterial adaptive responses to environmental challenges such as stress (1). Our 
previous study showed that the FQR-associated Thr-86-Ile mutation in GyrA greatly reduced 
the supercoiling activity of DNA gyrase both in vitro and in vivo (within Campylobacter 
cells). Whether the change in DNA supercoiling homeostasis alters the expression of certain 
genes in Campylobacter cells is unknown. To examine our hypothesis, we conducted 
transcriptome analysis to compare the mRNA level in FQS and FQR strains. One of the 
unregulated genes identified by DNA microarray is flaA, which encodes the major subunit of 
flagellum and is essential for the motility and colonization of Campylobacter (18, 44). 
Although 62301R33 and 62301S2 have similar motility, and both have intact flagellar 
structures when observed by electron microscopy, it is still possible that the increased 
expression of flaA may have functional consequences in vivo by facilitating the adaptation of 
62301R33 in the intestine, contributing to the enhanced fitness. However, the difference in 
the expression level of FlaA was be detected using immunoblotting (data not shown). This 
suggests that the transcriptional change is not reflected at the translational level.  
 
One interesting finding from the microarray results is that among the 17 upregulated 
genes in 62301R33, 11 are known to be controlled by the Fur regulator and their expression 
is increased in iron-limited conditions (24, 36). One of the upregulated genes is ChuA 
(Cj1614) which functions as a haemin receptor involved in iron uptake. Inactivation of the 
chuA gene rendered Campylobacter unable to grow in media in which haemin was the sole 
iron source (43). Cj1613c, which is immediately upstream of chuA and divergently 
transcribed, encodes an orthology (39% aa identity) of HugZ, which is involved in haeme 
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utilization (20, 23, 43). Recently, Pfam domain  pyridoxamine 5'-phosphate oxidase, which is 
a flavin mononucleotide (FMN) flavoprotein that catalyses the oxidation of pyridoxamine-5-
P (PMP) and pyridoxine-5-P (PNP) to pyridoxal-5-P (PLP), was identified within CDS of 
Cj1613 (19). ExbB1 (Cj0179) is a biopolymer transport protein and it also involved in 
transport of iron. Cj1661 encodes the ferric-binding protein of a putative ABC transport 
system. The protein encoded by Cj0426 and Cj0427, which overlap 10 nucleotides and are 
co-transcribed, are likely to form an ABC transport system. Although cj0426 is not on the list 
of known genes regulated by iron stress, expression of cj0427 was increased under iron-
limited conditions (24), suggesting that cj0426 might also be subject to iron regulation. 
Cj0334 and Cj1664 encode proteins involved in oxidative stress response, which is known to 
be regulated by iron concentration (7, 43). AhpC (Cj0334) is an important determinant of the 
ability of Campylobacter to survive oxidative and aerobic stress (7). Insertional mutagenesis 
of the ahpC gene resulted in an increased sensitivity to oxidative stresses. The iron-regulated 
expression of AhpC might also be significant in survival of Campylobacter in the intestinal 
epithelium of infected chickens (7). These results strongly suggest that the iron-response 
system is enhanced in FQR Campylobacter. Since iron is essential for microbial physiology 
and free iron is limited to the bacterial organism in animal hosts (24, 36), it is possible that 
the changed DNA supercoiling homeostasis in FQR Campylobacter increases the expression 
of the genes involved in iron stress response, which facilitate the iron acquisition and 
subsequently contributes to the enhanced in-host fitness. 
 
We also used 2-D DIGE method to compare the protein profiles between the FQR and 
FQS Campylobacter grown in laboratory media. 2-D DIGE is an advanced version of 
classical two-dimensional gel electrophoresis (2-D PAGE). Compared to classical 2-D PAGE, 
2-D DIGE has many advantages. First, in 2-D DIGE, the protein samples are pre-labeled 
with fluorescent dyes (CyDye) and then separated by 2D-PAGE. Different protein samples 
are labeled with different fluorescent dyes, mixed together and separated by the identical gel. 
Analyzing multiple samples on one 2-D DIGE rather than running single samples on 
individual 2D-PAGE gels reduces experimental gel-to-gel variations, which are the most 
severe problem in the gel-based proteomics. Second, fluorescent dyes (CyDye technique ) 
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used in 2-D DIGE have much more sensitivity than Coomassie blue and silver staining used 
in traditionally 2D-PAGE gels. Third, with silver and Coomassie staining, the gels need to be 
fixed and stained / destained using time-consuming techniques. Gels are then compared using 
computer software for changes in protein expression. However with DIGE, immediately after 
completion of electrophoresis each gel is scanned multiple times by laser scanners with 
different wavelengths for different CyDye used. The multiple images obtained by 2-D DIGE 
are analyzed by the image software such as DeCyder software. The normalization of Cy5 
intensity with Cy3 intensity is automatically achieved for all protein spots by the software 
and subtle changes in protein expression detected very accurately. Using proteomics, we 
identified 42 protein spots that were differentially present between 62301R33R and 
62301R33S. Among the 10 proteins that were upregulated in 62301R33R, 3 are involved in 
energy metabolism and 5 are involved in macromolecule metabolism. Two of the most 
upregulated proteins were both identified as  flavodoxin (FldA), which is a small FMN-
containing electron transferases (16). It functions as the electron acceptor of the pyruvate-
oxidoreductase complex (POR) that catalyzes pyruvate-oxidative decarboxylation to produce 
NADPH (39). Several studies have shown that flavodoxin is an essential protein for the 
survival of bacteria. Inactivation of FldA precludes the survival of Helicobacter pylori, 
which is a microaerophlic pathogen that is a close relative to C.jejuni (13). fldA is a vital 
gene in E. coli and a FldA mutation is lethal for E. coli under both aerobic and anaerobic 
stress conditions (16). In Campylobacter, the expression of fldA is also upregulated in iron-
limited conditions (24). This result plus the results from DNA microarray strongly suggest 
that the iron-response system is enhanced in FQR Campylobacter.  
 
No significant correlation between the microarray data and proteomic data was found 
in this study. Since posttranscriptional mechanisms control the turnover of proteins and the 
posttranscriptional modifications of proteins, it is not surprising to see the inconsistency 
between the mRNA and protein data. Similar findings have been reported in other studies (4, 
22). Since the whole genome sequence of C.jejuni S3B (from which all of the isolates used in 
this study were derived) is not available, we used the DNA microarray designed from strain 
NCTC 11168. Thus there is a possibility that the genes that are uniquely present in the S3B 
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series may not be detected by the microarray even though their expression is altered in 
62103R33. On the other hand, proteomics is capable of identifying all protein spots that show 
differential production between the paired strains. Due to budget constraints, we were not 
able to identify all of the 42 protein spots. Further work is needed to identify the remaining 
spots, which might reveal genes that were detected by the DNA microarray. In addition, 
whole cell proteins were used in the proteomics work, which might reduce the sensitivity of 
detecting expression changes of low-abundance proteins. Thus, fractioning cell proteins prior 
to 2-D DIGE may be needed to further enhance the detection sensitivity of the proteomics 
method. Nevertheless, our DNA microarray and proteomics studies revealed multiple 
changes in gene expression and protein production in FQR Campylobacter carrying the Thr-
86-Ile mutation in GyrA. Future research will be needed to assess the contribution of the 
altered gene expression to the enhanced fitness of FQR Campylobacter in chickens.  
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Table 1. Bacterial strains used in this study 
Table 1 Bacterial strains used in this study 
 Strains 
S3B 
nt mutation 
in gyrA 
aa mutation 
in GyrA 
Genotype 
 
MIC 
(µg/ml)  
62301S2 None None gyrA (Thr-86)  0.125 FQS 
strain 62301R33S None None Cj1028c::Cmr; gyrA (Thr-86) 0.125 
62301R33 C257T Thr-86-Ile gyrA (Ile-86) >32 FQR 
strains 62301R33R C257A Thr-86-Ile Cj1028c::Cmr gyrA (Ile-86) >32 
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Table 2. Genes upregulated in the FQR strain identified by DNA microarray 
Table 2 Genes upregulated in the FQR strain identified by DNA microarray 
Gene ID Description Bayesian P Fold change  
(Microarray) 
Fold 
Change 
(RT-PCR)# 
Cj1339c flaA; encoding the major 
flagellin subunit 9.75E-05 3.4 24 
*Cj1613c Ortholog of hugZ involved in 
haemin utilization 1.42E-03 2.9 3.9 
Cj0426 Probable ABC transporter 
ATP-binding protein 5.83E-03 2.0 4.2 
*Cj0427 Hypothetical protein; co-
transcribed with Cj0426 4.34E-03 1.7 3.0 
*Cj1614 chuA, Haemin uptake system 
outer membrane receptor  6.34E-03 2.1 2.3 
*Cj1384c Hypothetical protein 6.99E-03 2.2 2.0 
Cj1002c Phosphohistidine phosphatase 
SixA 9.95E-03 2.4 2.5 
*Cj1383C Hypothetical protein 1.58E-02 2.1 NT 
*Cj0176C Ferric-binding protein 1.32E-02 2.0 NT 
*Cj0334 AhpC (involved in oxidative 
stress) 4.76E-02 1.6 NT 
*Cj0179 ExbB1; transport protein 1.25E-02 1.9 NT 
*Cj1661 Putative ABC transporter 
protein; ferric-binding protein 2.61E-02 1.8 NT 
*Cj1664 Thioredoxin 3.14E-02 1.9 NT 
*Cj0089 Probable lipoprotein 4.52E-02 1.6 NT 
Cj1626c Probable periplasmic protein 2.23E-02 1.8 NT 
Cj0200c Probable periplasmic protein 4.34E-02 1.7 NT 
Cj0843c Probable secreted 
transglycosylase 4.7-E-02 1.6 NT 
* Genes whose expression is known to be upregulated under iron-limited conditions. 
# Means of three independent PCR experiments. NT, not tested. 
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Table 3. Differentially expressed protein spots between 62301R33R and 62301R33S 
identified by 2-D DIGE 
Table 3 Differentially expressed protein spots between 62301R33R and 62301R33S identified by 2-D DIGE 
Assigned spot No. Volume Ratio (62301R33R/62301R33S) 
1 1.66 
2 1.68 
3 -2.83 
4 1.56 
5 1.73 
6 1.84 
7 1.8 
8 1.84 
9 2.45 
10 3.89 
11 5.92 
12 9.53 
13 3.65 
14 1.44 
15 2.73 
16 1.6 
17 1.64 
18 -2.22 
19 -1.69 
20 1.48 
21 1.77 
22 1.51 
23 2.42 
24 1.91 
25 3.96 
26 3.76 
27 3.1 
28 17.52 
29 16.84 
30 8.77 
31 12.75 
32 4.92 
33 3.29 
34 2.72 
35 3.58 
36 3.81 
37 3.39 
38 2.69 
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Table 3. Differentially expressed protein spots between 62301R33R and 62301R33S 
identified by 2-D DIGE (Continued) 
 
 
Assigned spot No. 
Volume Ratio 
(62301R33R/62301R33S) 
39 1.6 
40 1.72 
41 1.6 
42 1.82 
43 1.48 
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Table 4. Differentially expressed proteins between 62301R33R and 62301R33S 
identified by 2-D DIGE 
Table 4 Differentially expressed proteins between 62301R33R and 62301R33S identified by 2-D DIGE 
Assigin
ed Spot 
No. 
Top Ranked Protein 
Name(Species)  
NBCInr 
accession No. 
Protein 
MW 
Protein 
PI 
No. of 
matched 
peptides 
Protien 
Score 
Protein 
Score 
C.I.% 
Fold 
Change 
2 flagellar hook protein FlgE  [C. jejuni RM1221]  
gi|57236913 89851 4.9 25 352 100 1.68 
13 
translation elongation factor 
Tu  
[C. coli RM2228]  
gi|57504721 43580.2 5.11 22 505 100 3.65 
20 hypothetical protein CJE0800 [C.jejuni RM1221]  
gi|57237003 25979.7 4.44 12 498 100 1.48 
23 
HAD-superfamily hydrolase, 
subfamily IA, variant 1 family 
protein  
[C. jejuni RM1221]  
gi|57238105 23722.1 6.08 11 229 100 2.42 
28 flavodoxin FldA [C.jejuni RM1221]  
gi|57238425 17124 3.89 7 486 100 17.52 
31 flavodoxin FldA [C.jejuni RM1221]  
gi|57238425 17124 3.89 4 168 100 12.75 
32 ribosomal protein L23  [C.jejuni subsp. jejuni 260.94]  
gi|86152332 10547.7 9.78 3 98 99.934 4.92 
41 
F0F1 ATP synthase subunit 
epsilon  
[C.jejuni RM1221]  
gi|57237115 13683 4.85 6 311 100 1.60 
42 DNA-binding protein HU  [C.jejuni subsp. jejuni 84-25]  
gi|88596497 6393.3 6.07 3 220 100 1.82 
43 50S ribosomal protein L7/L12 [C.jejuni RM1221]  
gi|57237531 13022.9 4.7 7 255 100 1.68 
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Fig. 1 Proteomic analysis of protein expression in Campylobacter 
Fig.1. Proteomic analysis of protein expression in Campylobacter. The image shows the 
overlay of 2-D DIGE patterns of 62301R33R versus 62301R33S. 62301R33R is in red and 
62301R33S is in green. The 42 differentially expressed protein spots were circled. Red 
indicates increased expression in 62301R33 and green indicates decreased expression in 
62301R33 in comparison to 62301R33S. Yellow indicates similar expression levels of 
between the two strains.  
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Fig. 2 Representative DeCyder display of relative abundance of selected protein spots in 
62301R33R versus 62301R33S 
Fig.2. Representative DeCyder display of relative abundance of selected protein spots in 
62301R33R versus 62301R33S (fold change in parentheses). A: FldA (17.52); B: translation 
elongation factor Tu (3.65); C: F0F1 ATP synthase subunit epsilon (1.60); and D: DNA-
bingding protein HU (1.82). 
(A) (B) 
(C) (D) 
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CHAPTER 6. GENERAL CONCLUSIONS  
 
The increasing FQ resistance rate of Campylobacter isolated from food-producing 
animals is a continuing concern for food safety and public health. How to reduce the 
occurrence and spread of FQR Campylobacter has become more and more important in the 
control of foodborne campylobacteriosis. Understanding the mechanisms underlying the 
rapid emergence of FQR and the enhanced fitness of FQR mutants in Campylobacter will help 
to reduce the occurrence and spread of FQR Campylobacter. 
 
In this project, we conducted a series of studies to determine how Campylobacter 
responds to FQ treatment, what facilitates the emergence of FQR mutants in Campylobacter, 
and what are the molecular mechanisms contributing to the enhanced fitness in FQR 
Campylobacter. In the first study, we examined the gene expression profiles of C. jejuni 
NCTC 11168 in response to treatment with ciprofloxacin (CIPRO) using microarray and 
found that 45 genes showed ≥1.5-fold (p <0.05) changes in expression when exposed to a 
suprainhibitory dose of CIPRO for 30 min. Most of the differentially-expressed genes 
involved in cell membrane biosynthesis and DNA repair are up-regulated, while the genes 
associated with cellular processes and energy metabolism are down-regulated following 
exposure to CIPRO. These findings suggest that C. jejuni modulates membrane biosynthesis, 
increases spontaneous mutation rates, and decreases metabolism in response to FQ treatment. 
One of the up-regulated genes was mfd (mutation frequency decline), which encodes a 
transcription-repair coupling factor involved in DNA repair. We found that in this study Mfd 
promotes the emergence of spontaneous FQR mutants and the development of FQR mutants 
under FQ treatments. These findings define a novel function of Mfd and significantly 
improve our understanding of the molecular mechanisms underlying the development of FQR 
Campylobacter. In the second study, we formally defined the role of the Thr-86-Ile mutation 
of GyrA in the enhanced fitness FQR Campylobacter in chickens by reverting the mutant 
allele. Then we conducted in vitro supercoiling assay using recombinant gyrases to assess the 
impact of various resistance-associated mutations on the enzymatic activities of DNA gyrase. 
We found that compared with that of the wild-type gyrase, the mutant gyrase with the Thr-
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86-Ile change showed greatly reduced supercoiling activity, while other GyrA mutations, 
although reduced the susceptibility of Campylobacter to ciprofloxacin, did not affect the 
supercoiling activity of the gyrase. Subsequently we determined the impact of the GyrA 
mutations on in vivo supercoiling (within Campylobacter cells) using a reporter plasmid. The 
in vivo supercoiling result was consistent with the in vitro supercoiling findings and revealed 
that the Thr-86-Ile mutation altered the DNA supercoiling state in FQR Campylobacter. In 
the third study, we examined if the altered function of mutant gyrase affected gene and 
protein expression in Campylobacter. We compared the differences in transcriptomes and 
protein profiles between FQR and FQS strains using DNA microarray and 2-D DIGE. The 
microarray data and 2-D DIGE data showed that the expression of multiple genes was altered 
between the FQR strains and FQS strains. Especially, the iron-response system and proteins 
involved in energy metabolism were upregulated in FQR Campylobacter, which may 
contribute to its enhanced fitness in the chicken host. Together, these findings from this 
project have significantly improved our understanding of the molecular mechanisms 
underlying the development of FQR Campylobacter and the fitness of the FQR 
Campylobacter. Findings from these studies will facilitate the design of strategies to reduce 
the emergence and spread of FQR Campylobacter. 
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